HIV-1 GROUP O ANTIGENS AND USES THEREOF

Abstract: The current invention relates to new HIV-1 group O antigens, nucleic acids encoding them, and the use of said antigens and/or nucleic acids as reagents in the diagnosis and prophylaxis of AIDS. It also relates to new HIV-1 group O strains comprising these antigens.

Description: HIV-1 group O antigens and uses thereof. The current invention relates to new HIV-1 group O antigens, nucleic acids encoding them, and the use of said antigens and/or nucleic acids as reagents in the diagnosis and prophylaxes of ADDS. It also relates to new HIV-1 group O strains comprising these antigens. The human immunodeficiency virus (HIV) is the responsible agent for the acquired immunodeficiency syndrome (ADDS) in humans. AIDS is usually associated with two distinct types of HTV: HIV-1 and HIV-2, initially described by Gallo et al. (1984) and Barre-Sinoussi et al. (1983) on the one hand, and Clavel et al. (1986) on the other hand. Although both types, HIV-1 and HIV-2, cause a dysfunction of the immune system and induce similar clinical symptoms in infected persons, they are genetically distinct (Clavel et al. 1986) Epidemiological studies have shown that the prevalence of HIV-2 infection is confined mainly to West Africa, whereas HIV-1 infection is a world wide problem. Numerous HIV-1 isolates have been obtained and sequenced from diverse geographical locations. At present, at least ten distinct subgroups or clades (A to J) of HIV-1 have been described, equidistantly related in phylogenetic analysis of the £«v-and/or gag-gene (Kostrikis et al.1995; Louwagie et al. 1993; Myers et al 1995). More recently, HIV-1 group O (for "Outlier") strains have been described as divergent viruses, belonging to an independent cluster (Charneau et al. 1994;Gϋrtler et al. 1994; Myers et al 1995; Sharp et al. 1994; Vanden Haesevelde et al. 1996), when compared to the vast majority of worldwide HIV-1 strains classified as group M (for "Major"). Although these two groups of viruses share the same genomic structure, the elevated level of divergence between them supports the hypothesis of independent origins. Most of the currently described group O strains have been characterized from Cameroonian patients or from patients who have travelled in Cameroon (De Leys et al. 1990; Gϋrtler et al. 1994; Loussert-Ajaka et al. 1995; Vanden Haesevelde et al. 1996). Group O infection is not restricted to Cameroon and its neighbouring countries, but it has also been documented in West, East, and Southern Africa (Peeters et al. 1996; Peeters et al. submitted). In addition, cases of group O infection have been described in several European countries (France, Spain, Germany, Norway) and in the USA (Centres for Disease control and Prevention 1996; Charneau et al. 1994; Hampl et al 1995; Soriano et al. 1996). Several hypotheses have been developed to explain the paradoxical observation that HTV-1 has been present in African countries for many decades (probably about a century) and that it has only become apparent over the past 15 years. The answer should probably take in account numerous parameters such as demographic, sociologic, ethologic, ethnologic, and virologic parameters. In a mathematical model, May and Anderson (1990) suggest that initial chains of infection were found in isolated populations at low rates with some 'sparks' thrown in the neighbouring villages, and the exponential epidemic has started when there was a sufficient number of fire-boxes. To date, no differences were observed between HIV-1 group M and O pathogenic potential even though a limited number of patients infected by these latter strains have been reported. However some of them have already died or reached stage IV in the CDC classification (Charneau et al. 1994; Gϋrtler et al. 1994; Loussert-Ajaka et al. 1995). It is possible that group O epidemics, compared to group M, could be rampant at this time. In the next years, it will therefore be extremely important to monitor the prevalence of these viruses, in Africa but also in the developed countries, to detect them as early as possible and to prevent a new HIV epidemic. HIV-1 group O strains present a public health challenge since they are documented to give incomplete and atypical HIV-1 Western blot profiles (Charneau et al. 1994; Gurtler et al. 1994). Some commercially available ELISA or rapid tests were unable to detect HIV-antibodies in HIV-1 group O infected patients (Loussert-Ajaka et al 1994; Simon et al. 1994). The distribution of group O infections may be much more wide spread than currently thought, because of a lack of adequate detection techniques. Moreover, whereas HIV-1 group M strains have been extensively studied and characterized as to their genetic variability, there is at present no clear view on the genetic diversity of strains belonging to HIV-1 group O. At present, sequence information on the complete genome is only available for the prototype isolates of HIV-1 group O, namely ANT70 (Vanden Haesevelde et al. 1994), MVP- 5180 (Gϋrtler et al. 1994), and VAU (Charneau et al. 1994). Some additional HIV-1 group O strains have been sequenced in the gag and env regions (for example WO 96/27013, WO 96/12809, EP 0727483). HIV-viruses show a high degree of genetic variability. In the case of HIV-1 viruses it is more or less accepted that at least one nucleotide change occurs during one replication cycle. Certain regions of the genome, for example those encoding structurally or enzymatically important proteins, may be rather conserved, but other regions, especially the e«v-region, may be subject of very high genetic variability. The envelope proteins of HTV are the viral proteins most accessible to immune attack, and much attention has been directed towards elucidating their structure and function. The env gene encoding the envelope proteins consists of hypervariable sequences (V-regions) alternated by more constant regions (C-regions) (Starcich et al, 1986; Willey et al, 1986). The envelope protein is first synthesized as a heavily glycosylated precursor protein (gpl60), which is later cleaved by a non-viral protease to generate a transmembrane protein, also referred to as gp41, and an outer surface protein often referred to as gpl20. One particular region of the gpl20 glycoprotein derived from the HIV-1 virus type has been studied extensively, namely the third hypervariable domain (V3) also known as the principal neutralizing determinant (PND) (Javaherian et al., 1989). The V3 domain of HIV-1 contains a loop structure of 35 amino acids (V3-loop) which is formed by a cysteine-cysteine disulfide bridge (Leonard et al. 1990). The gp41 protein contains an immunodominant domain (ID) as found in all retroviruses. For HIV-viruses, this domain has been divided in two distinct regions, corresponding to an immunosuppressive peptide (ISU) of about 17 aa, and a cysteine loop being the principal immunodominant domain (PID). The delineation of these respective regions in the gp41 protein is demonstrated in Figure 1. The genetic variability of HIV-viruses considerably complicates both diagnosis and prevention of HIV-infection. Sera from patients infected with unknown types of HIV- virus, may contain antibodies which are not detected by the current assay methods, which are based on (poly)peptide sequences of known viral strains. The detection of virus or viral antigen in certain samples, like organs for transplantation, or blood transfusion samples, may be missed due to the presence of hitherto unknown variant types. Variation may occur in those genomic regions which are considered to be important in future vaccines. Finally, it is not known at present if different genomic types may influence the course of the AIDS disease, i.e. its virulence and/or susceptibility for therapeutics. Therefore, there is a constant need for characterization and sequencing of new HIV- strains, and especially of new HIV-1 group O strains, which until now have only scarcely been characterized. Information on the genetic variability of this "Outlier" group may enable a more rational approach for optimization of diagnostic tests and for development of vaccines. Especially the variability of certain regions in the genome, known to be important target regions for the immune response, or for certain therapeutic drugs, is of utmost importance. New sequencing data may require the revision of existing diagnostic assays, and/or the development of new assays. Depending on the situation, it may be important to obtain a general detection of all HIV-infected samples, with a low number of false positives and false negatives, or to be able to differentiate different types of HIV-infection (such as HIV-1 group M, HIV-1 group O, HIV-2). It is the aim of the current invention to provide new nucleic acid and peptide sequences originating from HIV-1 group O strains. It is more specifically the aim of the current invention to provide nucleic acid and peptide sequences corresponding to the env-region of new HIV-1 group O strains, more particularly corresponding to the gplόO e«v-precursor protein region, and most particularly to the C2V3 region and the gp41 region. It is also an aim of the present invention to provide for new viral strains belonging to HIV- 1 group O. It is moreover an aim of the present invention to provide for antigens derived from said new HIV-1 group O strains. It is also an aim of the current invention to provide for nucleic acids derived from said new HIV-1 group O strains. It is also an aim of the present invention to provide antibodies reacting specifically with the antigens from the new HIV-1 group O strains. It is moreover an aim of the present invention to provide for probes hybridizing specifically with the nucleic acids of the new HIV-1 group O strains. It is moreover an aim of the present invention to use said antigens and/or antibodies and/or probes in a test for detecting the presence of HIV- infection and/or to differentiate different types of HIV-infection. It is thus also an aim of the present invention to provide for assays enabling the detection and/or differentiation of HIV-infections. It is finally also an aim of the present invention to provide for vaccine compositions providing protection against AIDS. The following definitions serve to illustrate the terms and expressions used in the different embodiments of the present invention as set out below: The term "polynucleic acid" corresponds to either double-stranded or single-stranded cDNA or genomic DNA or RNA containing at least 10, 20, 30, 40 or 50 contiguous nucleotides. Single stranded polynucleic acid sequences are always represented in the current invention from the 5' end to the 3' end. Polynucleic acids according to the invention may be prepared by any method known in the art for preparing polynucleic acids (e.g. the phosphodiester method for synthesizing oligonucleotides as described by Agarwal et al. (1972), the phosphotriester method of Hsiung et al. (1979), or the automated diethylphosphoroamidite method of Baeucage et al. (1981)). Alternatively, the polynucleic acids of the invention may be isolated fragments of naturally occurring or cloned DNA cDNA or RNA. The term "oligonucleotide" refers to a single stranded nucleic acid comprising two or more nucleotides, and less than 100 nucleotides. The exact size of an oligonucleotide depends on the ultimate function or use of said oligonucleotide. For use as a probe or primer the oligonucleotides are preferably about 5-50 nucleotides long, more preferably 10-30 nucleotides long. The oligonucleotides according to the present invention can be formed by cloning of recombinant plasmids containing inserts including the corresponding nucleotide sequences, if need be by cleaving the latter out from the cloned plasmids upon using the adequate nucleases and recovering them, e.g. by fractionation according to molecular weight. The probes according to the present invention can also be synthesized chemically, e.g. by automatic synthesis on commercial instruments sold by a variety of manufacturers. The nucleotides as used in the present invention may be ribonucleotides, deoxyribonucleotides and modified nucleotides such as inosine or nucleotides containing modified groups which do not essentially alter their hybridisation characteristics. Moreover, it is obvious to the man skilled in the art that any of the below-specified probes can be used as such, or in their complementary form, or in their RNA form (wherein T is replaced by U). The oligonucleotides used as primers or probes may also comprise or consist of nucleotide analogues such as phosphorothioates (Matsukura et al., 1987), alkylphosphorothioiates (Miller et al., 1979) or peptide nucleic acids (Nielsen et al., 1991; Nielsen et al., 1993) or may contain intercalating agents (Asseline et al., 1984). As most other variations or modifications introduced into the original DNA sequences of the invention, these variations will necessitate adaptions with respect to the conditions under which the oligonucleotide should be used to obtain the required specificity and sensitivity. However the eventual results of the hybridisation or amplification will be essentially the same as those obtained with the unmodified oligonucleotides. The introduction of these modifications may be advantageous in order to positively influence characteristics such as hybridization kinetics, reversibility of the hybrid-formation, biological stability of the oligonucleotide molecules, immobilization to solid phase etc. The term "probe" refers to single stranded sequence-specific oligonucleotides which have a sequence which is sufficiently complementary to hybridize to the target sequence to be detected. Preferably said probes are 90%, 95% or more homologous to the exact complement of the target sequence to be detected. These target sequences may be genomic DNA, genomic RNA or messenger RNA, or amplified versions thereof. The term "hybridizes to" refers to preferably stringent hybridization conditions, allowing hybridisation between sequences showing at least 90%, 95% or more homology with each other. The term "primer" refers to a single stranded DNA oligonucleotide sequence capable of acting as a point of initiation for synthesis of a primer extension product which is complementary to the nucleic acid strand to be copied. The length and the sequence of the primer must be such that they allow to prime the synthesis of the extension products. Preferably the primer is about 5-50 nucleotides long. Specific length and sequence will depend on the complexity of the required DNA or RNA targets, as well as on the conditions of primer use such as temperature and ionic strength. The fact that amplification primers do not have to match exactly with the corresponding template sequence to warrant proper amplification is amply documented in the literature (Kwok et al., 1990). The amplification method used can be either polymerase chain reaction (PCR; Saiki et al., 1988), ligase chain reaction (LCR; Landgren et al., 1988; Wu & Wallace, 1989; Barany, 1991), nucleic acid sequence-based amplification (NASBA; Guatelli et al., 1990; Compton, 1991), transcription-based amplification system (TAS; Kwoh et al., 1989), strand displacement amplification (SDA; Duck, 1990; Walker et al., 1992) or amplification by means of Qβ replicase (Lizardi et al., 1988; Lomeli et al., 1989) or any other suitable method to amplify nucleic acid molecules. The term "complementary" nucleic acids as used in the current invention means that the nucleic acid sequences can form a perfect base paired double helix with each other. The terms "polypeptide" and "peptide" are used interchangeably throughout the specification and designate a linear series of amino acids connected one to the other by peptide bonds between the alpha-amino and carboxy groups of adjacent amino acids. Polypeptides can be of a variety of lengths, either in their natural (uncharged) forms or in a charged form (=salt form), and either free of modifications such as glycosylation, side chain oxidation, or phosphorylation or containing these modifications. Preferably the peptides of the invention are less than 100 amino acids in length, more preferably less than 50, and even less than 30 amino acids long. It is well understood in the art that amino acid sequences contain acidic and basic groups, and that the particular ionization state exhibited by the peptide is dependent on the pH of the surrounding medium when the protein is in solution, or that of the medium from which it was obtained if the protein is in solid form. Also included in the definition are proteins modified by additional substituents attached to the amino acids side chains, such as glycosyl units, lipids, or inorganic ions such as phosphates, as well as modifications relating to chemical conversions of the chains, such as oxidation of sulfhydryl groups. Thus, "polypeptide" or its equivalent terms is intended to include the appropriate amino acid sequence referenced, subject to those of the foregoing modifications which do not destroy its functionality. The polypeptides of the invention, and particularly the fragments, can be prepared by classical chemical synthesis. The synthesis can be carried out in homogeneous solution or in solid phase. For instance, the synthesis technique in homogeneous solution which can be used is the one described by Houbenweyl in the book entitled "Methode der organischen chemie" (Method of organic chemistry) edited by E. Wunsh, vol. 15-1 et II. THIEME, Stuttgart 1974. The polypeptides of the invention can also be prepared in solid phase according to the methods described by Atherton and Shepard in their book entitled "Solid phase peptide synthesis" (LRL Press, Oxford, 1989). The polypeptides according to this invention can also be prepared by means of recombinant DNA techniques as described by Maniatis et al., Molecular Cloning: A Laboratory Manual, New York, Cold Spring Harbor Laboratory, 1982). In that case the polypeptides are obtained as expression products of the nucleic acids encoding said polypeptides. The expression occurs in a suitable host cell (eukaryotic or prokaryotic) which has been transformed with a vector in which the nucleic acid encoding the polypeptide has been inserted (called "insert"). The nucleic acid insert may have been obtained through classical genomic cloning techniques (screening of genomic libraries, shotgun cloning etc.), or by amplification of the relevant part in the viral genome, using suitable primer pairs and, for example, the polymerase chain reaction, or by DNA synthesis. The word "antigen" refers to a molecule which provokes an immune response (also called "immunogen"), or which can be recognized by the immune system (also called "antigen sensu strictu"). The immune response or the immune recognition reaction can be of the cellular or humoral type. The antigens of the current invention are all polypeptides or peptides, and therefore, the words "antigen" and "(poly)peptide" may be used interchangeably throughout the current invention. The term "antigenic determinant" or "epitope" refers to that portion of an antigenic molecule that is specifically bound by an antibody combining site. Epitopes may be determined by any of the techniques known in the art or may be predicted by a variety of computer prediction models known from the art. The terms "homologous" and "homology" are used in the current invention as synonyms for "identical" and "identity"; this means that amino acid sequences which are e.g. said to be 55% homologous, show 55% identical amino acids in the same position upon alignment of the sequences. The same definition holds for homologous nucleic acid sequences, i.e. nucleic acid sequences which are e.g. said to be 55% homologous, show 55% identical base pairs in the same position upon alignment of the sequences. The aims of the present invention have been met by the following embodiments. The present invention provides for an antigen, derived from the gpl60-e/?v precursor protein of a new HIV-1 group O strain, and characterized by an amino acid sequence comprising at least one of the following sequences: VQQMKI (SEQ ID NO 53), KIGPMSWYSMG (SEQ ID NO 54), MGLEKN (SEQ ID NO 55), IQQMKI (SEQ ID NO 56), KIGPLAWYSMG (SEQ ID NO 57), MGLERN (SEQ ID NO 58), QSVQEIKI (SEQ ID NO 59), KIGPMAWYSIG (SEQ ID NO 60), IGIGTT (SEQ ID NO 61), VQEIQT (SEQ ID NO 62), QTGPMAWYSIH (SEQ ID NO 63), IHLRTP (SEQ ID NO 64), IQEKI (SEQ ID NO 65), KIGPMSWYSMG (SEQ ID NO 66), MGIGQE (SEQ ID NO 67), SVQELRI (SEQ ID NO 68), RIGPMAWYSMT (SEQ ID NO 69), MTLERD (SEQ ID NO 70), SVQEIPI (SEQ ID NO 136), and/or at least one amino acid sequence chosen from the following group of sequences RNQQLLNLWGCKGRLIC (SEQ ID NO 71), CKGRLICYTSVQWNM (SEQ ID NO 72), LWGCKGRIVC (SEQ ID NO 73), SLWGCKGKLIC (SEQ ED NO 74), CKGKSIC (SEQ ID NO 75), CKGKIVC (SEQ LD NO 76), CRGRQVC (SEQ ID NO 77), CKGRLICYTSVH (SEQ ID NO 79), CKGNLIC (SEQ ID NO 80), CKGKMIC (SEQ ID NO 81 ), CKGRWC (SEQ ID NO 82), or a fragment of said antigen, said fragment consisting of at least 8, preferably 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 50 up to the maximum number of contiguous amino acids of the amino acid sequence of said antigen, and being characterized by the fact that it specifically reacts with antibodies raised against said antigen. The term "derived from" signifies that the antigen contains a fragment of the gpl60 env precursor protein. The expression "specifically reacts with" means that the antigen fragment is specifically recognized by antibodies raised against the antigen from which it is derived. Specificity of reaction may be preferably demonstrated using monoclonal antibodies raised against the antigen of the invention. Specificity of polyclonal antibodies may be obtained after absorption of said antibodies with the corresponding antigens of other HTV-l group O strains, in order to eliminate non-specific antibodies (=cross reactive antibodies) present in the polyclonal mixture. The expression "specifically react with" also means that sera taken from patients infected with the HIV-1 group O strain from which the antigen of the invention originates, show a preferential reaction with the antigen or antigen fragment of the invention, as compared to the reactivity with a corresponding antigen or antigen fragment of other HIV-1 group O strains (=control), under comparable reaction conditions. This preferential reaction may be measured quantitatively (e.g. ELISA absorption values) and should result in reactivity values which are at least 20%, 30%, 40% and preferably 50% higher than the reactivity with the control antigen. In practice, this means that the selected fragments of the above-mentioned antigens will always show at least one amino acid difference when compared in an alignment with the sequence of corresponding antigens of other HIV-1 group O isolates, such as ANT70, MVP5180, VAU or others. The above-mentioned amino acid sequences SEQ ID NO 53 to 70 and 136 originate from the central region in the V3 loop of the gpl60-e«v precursor protein of new HIV-1 group O strains, while the amino acid sequences represented by SEQ ID NO 71-77 and 79-82 originate from the gp41 -principal immunodominant domain (PID) of the gp 160-env precursor protein of the same HIV-1 group O strains. The current invention also provides for antigens consisting of any of the amino acid sequences represented by SEQ ID NO 53-70, 136, 71-77, 79-82, or consisting of an amino acid sequence according to any of SEQ ID NO 53-70, 136, 71-77, 79-82, whereby said sequence is extended at its N-terminal and/or C-terminal end with at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, up to 15 amino acids. The invention further provides for an antigen as described above, characterized by an amino acid sequence comprising at least one of the following amino acid sequences: CERPGNNSIQQMKIGPLAWYSMGLERNKSSISRLAYC (SEQ ED NO 83), CERPGNNSIQQMKIGPMAWYSMGLERNKSSISRLAYC (SEQ ID NO 84), CERPGNQSVQEIKIGPMAWYSIGIGTTPANWSRIAYC (SEQ ID NO 85), CERPGNQSVQEIKIGPMAWYSIGIGTTPTYNWSRIAYC (SEQ ID NO 86), CVRPWNQTVQEIQTGPMAWYSIHLRTPLANLSRIAYC (SEQ ID NO 87), CQRPGNLTIQEIKIGPMSWYSMGIGQEDHSKSRNAYC (SEQ ID NO 88), CERPYYQSVQELRIGPMAWYSMTLERDRAGSDIRAAYC (SEQ LD NO 89), CERPGNHTVQQMKIGPMSWYSMGLEKNNTSSRRAFC (SEQ ID NO 90), CERTWNQS VQEIPIGPMAWYSMS VELDLNTTGSRS ADC (SEQ ID NO 135), and/or at least one amino acid sequence chosen from the following group of sequences: DQQLLNLWGCKGRIVC YTS VKWN (SEQ LD NO 91 ), NQQLLNLWGCKGRLVCYTSVKWNK (SEQ ID NO 92), NQQLLNLWGCKGRLVCYTSVKWNN (SEQ ID NO 138), NQQRLNLWGCKGKMICYTSVPWN (SEQ ID NO 93), NQQLLNLWGCKGKSICYTSVKWN (SEQ ID NO 94), NQQLLNLWGCKGRLICYTSVQWN (SEQ ID NO 95), NQQRLNLWGCKGKMICYTSVKWN (SEQ ID NO 96), NQQLLNLWGCKGNLIC YTS VKWN (SEQ ID NO 97), NQQLLNLWGCRGRQVCYTSVIWN (SEQ ID NO 98), SQQLLNLWGCKGRLICYTSVHWN (SEQ ID NO 99), NQQLLNLWGCKGRIVCYTSVKWN (SEQ ID NO 100), NQQLLNSWGCKGKIVCYTAVKWN (SEQ ID NO 101 ), NQQLLSLWGCKGKLICYTSVKWN (SEQ ID NO 102), NQQLLNLWGCKGRLVC YTS VQWN (SEQ ID NO 137), or a fragment of said antigen, said fragment consisting of at least 8, preferably 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 50 up to the maximum number of contiguous amino acids of the amino acid sequence of said antigen, and being characterized by the fact that it specifically reacts with antibodies raised against said antigen. The above-mentioned amino acid sequences SEQ ED NO 83 to 90 and 135 represent the V3 loop region of the gpl60-env precursor protein of new HIV-1 group O strains, while the amino acid sequences SEQ ID NO 91 to 102, 137 and 138 originate from the gp41- immunodominant domain (ID) of the gpl60- env precursor protein of the same HIV-1 group O strains. The current invention also provides for antigens consisting of any of the amino acid sequences represented by SEQ ID NO 83-102, 135, 137 and 138 or consisting of an amino acid sequence according to any of SEQ ID NO 83-102, 135, 137 and 138, whereby said sequence is extended at its N-terminal and/or C-terminal end with at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, up to 15 amino acids. The invention further provides for antigens as above-defined, characterized by an amino acid sequence comprising at least one of the amino acid sequences represented by SEQ ID NO 2, SEQ ID NO 4, SEQ ID NO 6, SEQ ID NO 8, SEQ ID NO 10, SEQ ID NO 12, SEQ ID NO 14, SEQ ID NO 16, SEQ ID NO 18, SEQ ID NO 20, SEQ ID NO 22, SEQ ID NO 24, SEQ ID NO 26, SEQ K) NO 28, SEQ LD NO 30, SEQ ID NO 32, SEQ ID NO 34, SEQ ID NO 36, SEQ ID NO 38, SEQ ID NO 40 as shown in the alignment on Figure 1, and/or at least one of the amino acid sequences represented by SEQ ID NO 42, SEQ ID NO 44, SEQ ID NO 46, SEQ ID NO 48, SEQ ID NO 50, or SEQ ID NO 52 as shown in the alignment on Figure 2, and/or the amino acid sequence represented by SEQ ID NO 134, or a fragment of said antigen, said fragment consisting of at least 8, preferably 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 50 up to the maximum number of contiguous amino acids of any of the sequences represented by SEQ ID NO 2, SEQ ED NO 4, SEQ ID NO 6, SEQ LD NO 8, SEQ LD NO 10, SEQ ID NO 12, SEQ ID NO 14, SEQ LD NO 16, SEQ LD NO 18, SEQ ID NO 20, SEQ ID NO 22, SEQ ID NO 24, SEQ ID NO 26, SEQ ID NO 28, SEQ ID NO 30, SEQ ID NO 32, SEQ ID NO 34, SEQ ID NO 36, SEQ ED NO 38, SEQ ID NO 40, SEQ ID NO 42, SEQ ID NO 44, SEQ ID NO 46, SEQ ID NO 48, SEQ ID NO 50, SEQ ID NO 52, or SEQ ID NO 134, with said antigen fragment characterized by the fact that it specifically reacts with antibodies raised against the antigen from which it is derived. Furthermore, the invention provides for an antigen as above-defined, characterized by an amino acid sequence consisting of at least one of the following sequences: SEQ ID NO 2, SEQ ID NO 4, SEQ ID NO 6, SEQ ro NO 8, SEQ ro NO 10, SEQ ID NO 12, SEQ ID NO 14, SEQ ID NO 16, SEQ ID NO 18, SEQ ID NO 20, SEQ ED NO 22, SEQ ID NO 24, SEQ ID NO 26, SEQ ED NO 28, SEQ ID NO 30, SEQ ID NO 32, SEQ ED NO 34, SEQ ID NO 36, SEQ ID NO 38, SEQ ED NO 40, SEQ ID NO 42, SEQ ED NO 44, SEQ ID NO 46, SEQ ID NO 48, SEQ ID NO 50, SEQ ID NO 52, or the amino acid sequence represented by SEQ ID NO 134 or a fragment of said antigen, said fragment consisting of at least 8, preferably 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 50 up to the maximum number of contiguous amino acids of any of the sequences represented by SEQ ID NO 2, SEQ ID NO 4, SEQ ID NO 6, SEQ ID NO 8, SEQ ID NO 10, SEQ ro NO 12, SEQ ID NO 14, SEQ ID NO 16, SEQ ID NO 18, SEQ ro NO 20, SEQ ED NO 22, SEQ ED NO 24, SEQ ID NO 26, SEQ ID NO 28, SEQ ID NO 30, SEQ ID NO 32, SEQ ED NO 34, SEQ ID NO 36, SEQ ID NO 38, SEQ LD NO 40, SEQ ID NO 42, SEQ ID NO 44, SEQ ID NO 46, SEQ ID NO 48, SEQ ID NO 50, SEQ ro NO 52, or SEQ ID NO 134, with said antigen fragment characterized by the fact that it specifically reacts with antibodies raised against the antigen from which it is derived. It is to be noted that all the above-mentioned amino acid sequences originate from HIV-1 group O strains, which have until now never been described. More particularly, as is shown further in the examples section, the new amino acid sequences originate from the following strains: The amino acid sequences represented by SEQ ID NO 2, 4, 42, 73, 59, 60, 61, 73, 85, 86, 100 originate from the gplόO env precursor antigen isolated from a HIV-1 group O strain termed MP340, or a quasi-species thereof. The amino acid sequences represented by SEQ ID NO 6, 8, 44, 56, 57, 58, 82, 83, 84, 138 originate from the gplόO env precursor antigen isolated from a HIV-1 group O strain termed FAB A, or alternatively termed MP331, or a quasi-species thereof. The amino acid sequences represented by SEQ ID NO 10, 12, 46, 62, 63, 64, 73, 87, 100 originate from the gplόO env precursor antigen isolated from a HIV-1 group O strain termed MP450, or a quasi-species thereof. The amino acid sequences represented by SEQ ID NO 14, 16, 48, 65, 66, 67, 76, 88, 101 originate from the gplόO env precursor antigen isolated from a HIV-1 group O strain termed MP448, or a quasi species thereof. The amino acid sequences represented by SEQ ID NO 18, 50, 53, 54, 55, 73, 90, 91 originate from the gp 160 env precursor antigen isolated from a HIV- 1 group O strain termed 189, or a quasi-species thereof. The amino acid sequences represented by SEQ ID NO 40, 52, 68, 69, 70, 71, 89, 95 originate from the gplόO env precursor antigen isolated from a HIV-1 group O strain termed MP539, or a quasi-species thereof. The amino acid sequences represented by SEQ ID NO 20 and 92 originate from the gρl60 env precursor antigen isolated from a HIV-1 group O strain termed 320, or a quasi-species thereof. The amino acid sequences represented by SEQ ID NO 22, 80 and 97 originate from the gplόO env precursor antigen isolated from a HIV-1 group O strain termed BSD422, or a quasi - species thereof. The amino acid sequences represented by SEQ ID NO 24, 79 and 99 originate from the gplόO env precursor antigen isolated from a HIV-1 group O strain termed KGT008, or a quasi- species thereof. The amino acid sequence represented by SEQ ID NO 26 originates from the gplόO env precursor antigen isolated from a HIV-1 group O strain termed MP575, or a quasi-species thereof. The amino acid sequences represented by SEQ LD NO 28, 72 and 95 originate from the gplόO env precursor antigen isolated from a HIV-1 group O strain termed BSD 189, or a quasi- species thereof. The amino acid sequences represented by SEQ ID NO 30, 77 and 98 originate from the gp 60 env precursor antigen isolated from a HIV-1 group O strain termed BSD649, or a quasi- species thereof. The amino acid sequences represented by SEQ ID NO 32, 81 and 96 originate from the gplόO env precursor antigen isolated from a HIV-1 group O strain termed BSD242, or a quasi- species thereof. The amino acid sequences represented by SEQ ID NO 34, 81 and 93 originate from the gplόO env precursor antigen isolated from a HIV-1 group O strain termed 533, or a quasi-species thereof. The amino acid sequences represented by SEQ ID NO 36, 75 and 94 originate from the gplόO env precursor antigen isolated from a HIV-1 group O strain termed 772P94, or a quasi- species thereof. The amino acid sequences represented by SEQ ID NO 38, 74 and 102 originate from the gplόO env precursor antigen isolated from a HIV-1 group O strain termed MP95B, or a quasi- species thereof. The amino acid sequences represented by SEQ ID NO 134, 135, 136, and 137 originate from the gplόO env precursor antigen isolated from a HIV-1 group O strain termed MP645, or a quasi-species thereof. It is noted that the amino acid sequence represented by SEQ ID NO 73 is characteristic for the gp41 immunodominant region of at least the following new HIV-1 group O strains: MP340, MP450, and 189. The current invention therefore specifically relates to ewv-derived antigens comprising the characteristic sequence represented by SEQ ID NO 73, as well as virus strains containing these antigens. It is also noted that the amino acid sequence represented by SEQ ID NO 81 is characteristic for the gp41 immunodominant region of at least the following new HIV-1 group O strains: BSD242 and 533. The current invention therefore specifically relates to e«v-derived antigens comprising the characteristic sequence represented by SEQ ID NO 81, as well as virus strains containing these antigens. It is also noted that the amino acid sequence represented by SEQ ID NO 95 is characteristic for the gp41 immunodominant region of at least the following new HIV-1 group O strains: MP539 and BSD189. The current invention therefore specifically relates to e«v-derived antigens comprising the characteristic sequence represented by SEQ ID NO 95, as well as virus strains containing these antigens. The term "quasi-species" refers in general to the group of related but genetically and possibly biologically different viruses (also called "variants") that an infected individual harbors. The term "related" means that the "variants" all arise from a single infectious agent, in this case from a single HIV-1 group O strain. It has been calculated that an HIV-infected patient carries about 10 6 to 10 s genetically distinct HIV- variants, which are generated by the high error rate of reverse transcriptase and the high turnover rate in vivo. In the context of the current description the term "quasi-species" refers also to a strain isolated from the quasi-species "group" as above- defined. The term "genetically different" means that the nucleic acid sequence of the genome of one strain shows at least one nucleotide difference with the corresponding sequence of another strain belonging to the same quasi-species. The term "biologically different" means that some strains of a quasi-species may have different biological characteristics compared to the biological characteristics of other strains from the same quasi-species. These biological characteristics may encompass for example the HIV-1 cell tropism, viral virulence, the capacity to induce syncytia, etc. Nucleic acid sequences originating from quasi-species differ from each other but always show a high percentage of homology, most often a homology of 90%, 95% or higher. The same holds for the sequence of polypeptides originating from quasi-species. Homology percentages on the protein level usually exceed 95%, 96%, 97%, 98%, or even 99%. These percentages of homology count for the comparison of sequence stretches which are at least 100 nucleotides (about 33 amino acids), and preferably 200, 300 or more nucleotides long (66, 100 or more amino acids). It has to be understood that, when very short sequence stretches are compared (e.g. stretches of about 30 nucleotides, or 10 amino acids) the homology ranges may be much lower, if these short sequence stretches contain the mutual differences. Examples of sequences originating from "quasi-species" are provided further in the examples section, where gp41- and C2V3- nucleotide and amino acid sequences of certain strains belonging to the same "quasi-species" are compared to each other. For example, for strains MP340, FAB A, MP450 and MP448 gp41 -nucleic acid sequences have been determined on different samples, originating from the same patient, i.e. on serum samples and on peripheral blood monocyte (PBMC) samples. Table 2 shows that, in these specific examples, homology percentages vary from 95% to 100% between gp41 -nucleic acid sequences determined on serum samples as compared to PBMC-samples. It is to be understood that the amino acid and nucleic acid sequences of the current invention also encompass those sequences which are not explicitly recited, but which have been determined on "quasi-species" of the respective viral strains. As indicated above, these "variant" sequences show a homology range of at least 90%, preferably 95% with the sequences which are specifically recited in the current application. The above-mentioned antigens are polypeptide or peptide molecules, which are characterized by the above-mentioned amino acid sequences. It has to be understood however, that these (poly)peptides may be modified by for example glycosylation, side chain oxidation or phosphorylation as explained above. A very particular type of side chain oxidation is cyclisation by bridge formation between the -SH groups of two cysteine residues in the same (poly)peptide chain. The cyclic (poly)peptides formed in this way by S-S bridging may be particularly suitable to expose epitopes located in the loop structure. Epitopes presented in this manner may be in a better shape to be recognized by the immune system, and more particularly by antibodies possibly present in the serum of HIV-infected persons. A preferential embodiment of the current invention provides for any of Lhe above- mentioned (poly)peptides in a cyclic form. Cyclisation may occur between two cysteine residues which are present in the above-cited amino acid sequences. For example, cyclic peptides with a loop structure of about 6 amino acids long may be formed with the amino acid sequences represented by e.g. SEQ ID NO 71 to 82, and 91 to 102, and 137. Another example are the V3-loop peptides of about 35 amino acids long, which may be formed by cyclisation of the cysteine residues of the amino acid sequences represented by e.g. SEQ ID NO 83 to 90, and 135. On the other hand, cyclisation may also be induced in amino acid sequences which do not contain two cysteine residues naturally, but which have been extended with one or two cysteine residues at their extremities, or at in internal position inside the amino acid chain. The current invention therefore also refers to (poly)peptides characterized by any of the above-mentioned amino acid sequences, modified by addition of one or several cysteine residues, at the C-terminal and/or N-terminal extremity and/or inside the (poly)peptide chain. Another particular type of modification includes the extension of the N-terminal and/or C-terminal end of the (poly)peptide antigen by linker sequences, said linker sequences comprising for example additional amino acids or other molecules (such as for example biotin). The addition of linker sequences to the polypeptide antigen may have several advantages such as: - a more efficient immobilisation on a solid substrate, - a more efficient presentation of the immunoreactive epitope(s) in the (poly)peptide, - linkage to other antigenic determinants... A preferential embodiment therefore includes antigens or antigen fragments comprising any of the above-mentioned amino acid sequences, extended with linker sequences. It has to be understood that the above-mentioned (poly)peptide antigens of the invention may be prepared by different methods known in the art. They may be prepared by synthetic means as described above, or they may be produced by recombinant DNA technology. In the latter case, they are the result of the expression of the nucleic acids encoding said antigens or antigen fragments in an appropriate host cell. The invention also relates to a recombinant vector for the expression of any of the above- mentioned polypeptides, recombinant host cells expresssing these polypeptides, and processes for the recombinant expression of these polypeptides; said tools for recombinant expression are well known by anyone skilled in the art, and have been described in more detail for example in WO96/13590. The invention further provides for a (poly)nucleic acid encoding any of the above- mentioned (poly)peptide antigens. More particularly, the current invention provides for a polynucleic acid comprising a nucleotide sequence chosen from the group of (I) a nucleotide sequence represented by SEQ ED NO 1, SEQ ID NO 3, SEQ ID NO 5, SEQ ID NO 7, SEQ ED NO 9, SEQ ID NO 11, SEQ ID NO 13, SEQ ID NO 15, SEQ ID NO 17, SEQ ID NO 19, SEQ ID NO 21, SEQ ID NO 23, SEQ ID NO 25, SEQ ID NO 27, SEQ ID NO 29, SEQ ro NO 31, SEQ ED NO 33, SEQ ID NO 35, SEQ ID NO 37, SEQ ID NO 39, SEQ ID NO 41, SEQ ID NO 43, SEQ ID NO 45, SEQ ID NO 47, SEQ ID NO 49, or SEQ ID NO 51, SEQ ED NO 106 or (ii) a nucleotide sequence complementary to a sequence according to (I), or (iϋ) a nucleotide sequence showing at least 95%, preferably 96%, 97%, 98% and most preferably 99% homology to a sequence according to (I), or (iv) a nucleotide sequence according to (I) whereby T is replaced by U, or (v) a nucleotide sequence according to (I) whereby at least one nucleotide is substituted by a nucleotide analogue. It is to be noted that, as will be shown further on in the examples section, the above- mentioned polynucleic acids all originate from the e«v-gene of new HIV-1 group O strains. The nucleic acid sequences represented by SEQ ID NO 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37 and 39 correspond to the region encoding the gp41 -immunodominant domain in the e«v-gene, while the nucleic acid sequences represented by SEQ ID NO 41, 43, 45, 47, 49, and 51 correspond to the region encoding the C2V3 region in this same e«v-gene. The nucleotide sequence represented by SEQ ID NO 106 is illustrated in figure 8 A, and comprises the full e«v-gene of a new HIV-1 group O strain, termed MP645, together with additional accompanying genes. The nucleotide sequences mentioned above under item (iii) represent variant nucleic acid sequences which may be isolated e.g. from strains belonging to the same quasi-species. More particularly, the invention provides for a polynucleic acid consisting of a nucleotide sequence chosen from the group of (I) a nucleotide sequence represented by SEQ ro NO 1, SEQ ED NO 3, SEQ ro NO 5, SEQ ID NO 7, SEQ ID NO 9, SEQ ID NO 11, SEQ ID NO 13, SEQ ID NO 15, SEQ ro NO 17, SEQ ro NO 19, SEQ K) NO 21, SEQ ED NO 23, SEQ HD NO 25, SEQ ID NO 27, SEQ ID NO 29, SEQ ID NO 31, SEQ ID NO 33, SEQ ID NO 35, SEQ ID NO 37, SEQ ID NO 39, SEQ ED NO 41, SEQ ID NO 43, SEQ ED NO 45, SEQ ID NO 47, SEQ ID NO 49, or SEQ ID NO 51, SEQ ro NO 106 or (ii) a nucleotide sequence complementary to a sequence according to (I), or (ϋi) a nucleotide sequence showing at least 95%, preferably 96%, 97%, 98% and most preferably 99% homology to a sequence according to (I), or (iv) a nucleotide sequence according to (I) whereby T is replaced by U, or (v) a nucleotide sequence according to (I) whereby at least one nucleotide is substituted by a nucleotide analogue. The invention further provides for a nucleic acid fragment consisting of a sequence of at least 15, preferably 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 up to 50 contiguous nucleotides of the sequence of a polynucleic acid as specified above, and characterized by the fact that it selectively hybridizes to the polynucleic acid from which it is derived. The above-described nucleic acid fragment may be used as a specific hybridization probe for the detection of the nucleic acids of the current invention. The term "selectively hybridizing" means that the hybridization signal obtained after hybridization of the fragment with the nucleic acid from which it is derived, is more intense than the hybridization signal obtained when the fragment is hybridized to the corresponding nucleic acid from another HIV-1 group O strain, under the same stringent hybridization and wash conditions. In practice this means that the nucleic acid fragment will show at least one mismatched nucleotide with the sequence of the corresponding nucleic acid fragment of another HIV-1 group O strain. The term "stringent hybridization conditions" implies that the hybridization takes place at a temperature which is situated approximately between Tm and (Tm - 10°C), whereby Tm represents the calculated melting temperature of the target nucleic. It is generally known that the stringency depends on the percentage mismatches (=non-matching nucleotides upon alignment) present in the hybridizing duplex. According to a simplified formula, the hybridization temperature may be calculated as follows: Tm - 1.2 (% mismatch). A temperature decrease of 10°C implies a maximum percentage of allowed mismatches of 8.3%. The invention further provides for a nucleic acid fragment consisting of a sequence of at least 15, preferably 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 up to 50 contiguous nucleotides of the sequence of a polynucleic acid as specified above, and characterized by the fact that it selectively amplifies the polynucleic acid from which it is derived. The nucleic acid fragment as described above may be used as a specific amplification primer of the nucleic acids of the current invention. The term "selective amplification" refers to the fact that said nucleic acid fragment may initiate a specific amplification reaction of the nucleic acids of the invention (e.g. a polymerase chain reaction) in the presence of other nucleic acids, under appropriate amplification conditions. It means that, under the appropriate amplification conditions, only the nucleic acids of the invention will be amplified, and not the other nucleic acids possibly present. Preferred embodiments of the invention comprise polynucleic acids or fragments thereof as specified below. A polynucleic acid comprising SEQ ED NO 1, or a fragment consisting of at least 15, preferably 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, up to 50 contiguous nucleotides of said polynucleic acid, said fragment characterized by the fact that it selectively hybridizes to the polynucleic acid comprising SEQ ID NO 1. A polynucleic acid consisting of SEQ ID NO 1, or a fragment comprising at least 15, preferably 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 50 up to the maximum number of contiguous nucleotides of SEQ ID NO 1, said fragment characterized by the fact that it selectively hybridizes to the polynucleic acid consisting of SEQ ID NO 1. A polynucleic acid comprising SEQ ID NO 3, or a fragment consisting of at least 15, preferably 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 up to 50 contiguous nucleotides of said polynucleic acid, said fragment characterized by the fact that it selectively hybridizes to the polynucleic acid comprising SEQ ID NO 3. A polynucleic acid consisting of SEQ ID NO 3, or a fragment comprising at least 15, preferably 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 50 up to the maximum number of contiguous nucleotides of SEQ ID NO 3, said fragment characterized by the fact that it selectively hybridizes to the polynucleic acid consisting of SEQ ED NO 3. A polynucleic acid comprising SEQ ID NO 5, or a fragment consisting of at least 15, preferably 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 up to 50 contiguous nucleotides of said polynucleic acid, said fragment characterized by the fact that it selectively hybridizes to the polynucleic acid comprising SEQ ID NO 5. A polynucleic acid consisting of SEQ ID NO 5, or a fragment comprising at least 15, preferably 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 50 up to the maximum number of contiguous nucleotides of SEQ ID NO 5, said fragment characterized by the fact that it selectively hybridizes to the polynucleic acid consisting of SEQ ID NO 5. A polynucleic acid comprising SEQ ID NO 7, or a fragment consisting of at least 15, preferably 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 up to 50 contiguous nucleotides of said polynucleic acid, said fragment characterized by the fact that it selectively hybridizes to the polynucleic acid comprising SEQ ID NO 7. A polynucleic acid consisting of SEQ ID NO 7, or a fragment comprising at least 15, preferably 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 50 up to the maximum number of contiguous nucleotides of SEQ ID NO 7, said fragment characterized by the fact that it selectively hybridizes to the polynucleic acid consisting of SEQ ID NO 7. A polynucleic acid comprising SEQ ID NO 9, or a fragment consisting of at least 15, preferably 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 up to 50 contiguous nucleotides of said polynucleic acid, said fragment characterized by the fact that it selectively hybridizes to the polynucleic acid comprising SEQ ID NO 9. A polynucleic acid consisting of SEQ ID NO 9, or a fragment comprising at least 15, preferably 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 50 up to the maximum number of contiguous nucleotides of SEQ ID NO 9, said fragment characterized by the fact that it selectively hybridizes to the polynucleic acid consisting of SEQ ED NO 9. A polynucleic acid comprising SEQ ID NO 11, or a fragment consisting of at least 15, preferably 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 up to 50 contiguous nucleotides of said polynucleic acid, said fragment characterized by the fact that it selectively hybridizes to the polynucleic acid comprising SEQ ID NO 11. A polynucleic acid consisting of SEQ ED NO 11, or a fragment consisting of at least 15, preferably 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, up to 50 contiguous nucleotides of SEQ ID NO 11, said fragment characterized by the fact that it selectively hybridizes to the polynucleic acid consisting of SEQ ID NO 11. A polynucleic acid comprising SEQ ID NO 13, or a fragment consisting of at least 15, preferably 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 up to 50 contiguous nucleotides of said polynucleic acid, said fragment characterized by the fact that it selectively hybridizes to the polynucleic acid comprising SEQ ID NO 13. A polynucleic acid consisting of SEQ ID NO 13, or a fragment comprising at least 15, preferably 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 50, up to the maximum number of contiguous nucleotides of SEQ ID NO 13, said fragment characterized by the fact that it selectively hybridizes to the polynucleic acid consisting of SEQ ED NO 13. A polynucleic acid comprising SEQ ID NO 15, or a fragment consisting of at least 15, preferably 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 up to 50 contiguous nucleotides of said polynucleic acid, said fragment characterized by the fact that it selectively hybridizes to the polynucleic acid comprising SEQ ID NO 15. A polynucleic acid consisting of SEQ ID NO 15, or a fragment comprising at least 15, preferably 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 50 up to the maximum number of contiguous nucleotides of SEQ ID NO 15, said fragment characterized by the fact that it selectively hybridizes to the polynucleic acid consisting of SEQ ID NO 15. A polynucleic acid comprising SEQ ED NO 17, or a fragment consisting of at least 15, preferably 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 up to 50 contiguous nucleotides of said polynucleic acid, said fragment characterized by the fact that it selectively hybridizes to the polynucleic acid comprising SEQ ID NO 17. A polynucleic acid consisting of SEQ ID NO 17, or a fragment comprising at least 15, preferably 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 50 up to the maximum number of contiguous nucleotides of SEQ ID NO 17, said fragment characterized by the fact that it selectively hybridizes to the polynucleic acid consisting of SEQ ID NO 17. A polynucleic acid comprising SEQ ED NO 19, or a fragment consisting of at least 15, preferably 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 up to 50 contiguous nucleotides of said polynucleic acid, said fragment characterized by the fact that it selectively hybridizes to the polynucleic acid comprising SEQ ID NO 19. A polynucleic acid consisting of SEQ ID NO 19, or a fragment comprising at least 15, preferably 16, 17, 18, 19, 20, 21, 22, 23, 24, 25,50 up to the maximum number of contiguous nucleotides of SEQ ID NO 19, said fragment characterized by the fact that it selectively hybridizes to the polynucleic acid consisting of SEQ ID NO 19. A polynucleic acid comprising SEQ ID NO 21, or a fragment consisting of at least 15, preferably 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 up to 50 contiguous nucleotides of said polynucleic acid, said fragment characterized by the fact that it selectively hybridizes to the polynucleic acid comprising SEQ ID NO 21. A polynucleic acid consisting of SEQ ED NO 21, or a fragment comprising at least 15, preferably 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 50 up to the maximum number of contiguous nucleotides of SEQ ED NO 21, said fragment characterized by the fact that it selectively hybridizes to the polynucleic acid consisting of SEQ ID NO 21. A polynucleic acid comprising SEQ ID NO 23, or a fragment consisting of at least 15, preferably 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 up to 50 contiguous nucleotides of said polynucleic acid, said fragment characterized by the fact that it selectively hybridizes to the polynucleic acid comprising SEQ ID NO 23. A polynucleic acid consisting of SEQ ID NO 23, or a fragment comprising at least 15, preferably 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 50 up to the maximum number of contiguous nucleotides of SEQ ED NO 23, said fragment characterized by the fact that it selectively hybridizes to the polynucleic acid consisting of SEQ ID NO 23. A polynucleic acid comprising SEQ ID NO 25, or a fragment consisting of at least 15, preferably 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 up to 50 contiguous nucleotides of said polynucleic acid, said fragment characterized by the fact that it selectively hybridizes to the polynucleic acid comprising SEQ ID NO 25. A polynucleic acid consisting of SEQ ID NO 25, or a fragment consisting of at least 15, preferably 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, up to 50 contiguous nucleotides of SEQ ID NO 25, said fragment characterized by the fact that it selectively hybridizes to the polynucleic acid consisting of SEQ ID NO 25. A polynucleic acid comprising SEQ ID NO 27, or a fragment consisting of at least 15, preferably 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 up to 50 contiguous nucleotides of said polynucleic acid, said fragment characterized by the fact that it selectively hybridizes to the polynucleic acid comprising SEQ ED NO 27. A polynucleic acid consisting of SEQ ID NO 27, or a fragment comprising at least 15, preferably 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 50 up to the maximum number of contiguous nucleotides of SEQ ID NO 27, said fragment characterized by the fact that it selectively hybridizes to the polynucleic acid consisting of SEQ ID NO 27. A polynucleic acid comprising SEQ ID NO 29, or a fragment consisting of at least 15, preferably 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 up to 50 contiguous nucleotides of said polynucleic acid, said fragment characterized by the fact that it selectively hybridizes to the polynucleic acid comprising SEQ ID NO 29. A polynucleic acid consisting of SEQ ID NO 29, or a fragment comprising at least 15, preferably 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 50 up to the maximum number of contiguous nucleotides of SEQ ID NO 29, said fragment characterized by the fact that it selectively hybridizes to the polynucleic acid consisting of SEQ ID NO 29. A polynucleic acid comprising SEQ ID NO 31, or a fragment consisting of at least 15, preferably 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 up to 50 contiguous nucleotides of said polynucleic acid, said fragment characterized by the fact that it selectively hybridizes to the polynucleic acid comprising SEQ ID NO 31. A polynucleic acid consisting of SEQ ID NO 31, or a fragment comprising at least 15, preferably 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 50 up to the maximum number of contiguous nucleotides of SEQ ID NO 31, said fragment characterized by the fact that it selectively hybridizes to the polynucleic acid consisting of SEQ ID NO 31. A polynucleic acid comprising SEQ ID NO 33, or a fragment consisting of at least 15, preferably 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 up to 50 contiguous nucleotides of said polynucleic acid, said fragment characterized by the fact that it selectively hybridizes to the polynucleic acid comprising SEQ ID NO 33. A polynucleic acid consisting of SEQ ED NO 33, or a fragment comprising at least 15, preferably 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 50 up to the maximum number of contiguous nucleotides of SEQ ED NO 33, said fragment characterized by the fact that it selectively hybridizes to the polynucleic acid consisting of SEQ ID NO 33. A polynucleic acid comprising SEQ ID NO 35, or a fragment consisting of at least 15, preferably 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 up to 50 contiguous nucleotides of said polynucleic acid, said fragment characterized by the fact that it selectively hybridizes to the polynucleic acid comprising SEQ ID NO 35. A polynucleic acid consisting of SEQ ID NO 35, or a fragment comprising at least 15, preferably 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 50 up to the maximum number of contiguous nucleotides of SEQ ED NO 35, said fragment characterized by the fact that it selectively hybridizes to the polynucleic acid consisting of SEQ ID NO 35. A polynucleic acid comprising SEQ ID NO 37, or a fragment consisting of at least 15, preferably 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 up to 50 contiguous nucleotides of said polynucleic acid, said fragment characterized by the fact that it selectively hybridizes to the polynucleic acid comprising SEQ ID NO 37. A polynucleic acid consisting of SEQ ED NO 37, or a fragment comprising at least 15, preferably 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 50 up to the maximum number of contiguous nucleotides of SEQ ID NO 37, said fragment characterized by the fact that it selectively hybridizes to the polynucleic acid consisting of SEQ ID NO 37. A polynucleic acid comprising SEQ ED NO 39, or a fragment consisting of at least 15, preferably 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 up to 50 contiguous nucleotides of said polynucleic acid, said fragment characterized by the fact that it selectively hybridizes to the polynucleic acid comprising SEQ ID NO 39. A polynucleic acid consisting of SEQ ED NO 39, or a fragment comprising at least 15, preferably 16, 17, 18, 19, 20, 21, 22, 23, 24, 25,50 up to the maximum number of contiguous nucleotides of SEQ ID NO 39, said fragment characterized by the fact that it selectively hybridizes to the polynucleic acid consisting of SEQ ID NO 39. A polynucleic acid comprising SEQ ID NO 41, or a fragment consisting of at least 15, preferably 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 up to 50 contiguous nucleotides of said polynucleic acid, said fragment characterized by the fact that it selectively hybridizes to the polynucleic acid comprising SEQ ID NO 41. A polynucleic acid consisting of SEQ ED NO 41, or a fragment comprising at least 15, preferably 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 50 up to the maximum number of contiguous nucleotides of SEQ ID NO 41, said fragment characterized by the fact that it selectively hybridizes to the polynucleic acid consisting of SEQ ID NO 41. A polynucleic acid comprising SEQ ID NO 43, or a fragment consisting of at least 15, preferably 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 up to 50 contiguous nucleotides of said polynucleic acid, said fragment characterized by the fact that it selectively hybridizes to the polynucleic acid comprising SEQ ID NO 43. A polynucleic acid consisting of SEQ ED NO 43, or a fragment comprising at least 15, preferably 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 50 up to the maximum number of contiguous nucleotides of SEQ ID NO 43, said fragment characterized by the fact that it selectively hybridizes to the polynucleic acid consisting of SEQ ID NO 43. A polynucleic acid comprising SEQ ID NO 45, or a fragment consisting of at least 15, preferably 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 up to 50 contiguous nucleotides of said polynucleic acid, said fragment characterized by the fact that it selectively hybridizes to the polynucleic acid comprising SEQ ID NO 45. A polynucleic acid consisting of SEQ ED NO 45, or a fragment comprising at least 15, preferably 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 50 up to the maximum number of contiguous nucleotides of SEQ ID NO 45, said fragment characterized by the fact that it selectively hybridizes to the polynucleic acid consisting of SEQ ID NO 45. A polynucleic acid comprising SEQ ID NO 47, or a fragment consisting of at least 15, preferably 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 up to 50 contiguous nucleotides of said polynucleic acid, said fragment characterized by the fact that it selectively hybridizes to the polynucleic acid comprising SEQ ID NO 47. A polynucleic acid consisting of SEQ ID NO 47, or a fragment comprising at least 15, preferably 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 50 up to the maximum number of contiguous nucleotides of SEQ ID NO 47, said fragment characterized by the fact that it selectively hybridizes to the polynucleic acid consisting of SEQ ED NO 47. A polynucleic acid comprising SEQ ID NO 49, or a fragment consisting of at least 15, preferably 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 up to 50 contiguous nucleotides of said polynucleic acid, said fragment characterized by the fact that it selectively hybridizes to the polynucleic acid comprising SEQ ED NO 49. A polynucleic acid consisting of SEQ ID NO 49, or a fragment comprising at least 15, preferably 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 50 up to the maximum number of contiguous nucleotides of SEQ ED NO 49, said fragment characterized by the fact that it selectively hybridizes to the polynucleic acid consisting of SEQ ID NO 49. A polynucleic acid comprising SEQ ED NO 51, or a fragment consisting of at least 15, preferably 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 up to 50 contiguous nucleotides of said polynucleic acid, said fragment characterized by the fact that it selectively hybridizes to the polynucleic acid comprising SEQ ED NO 51. A polynucleic acid consisting of SEQ ID NO 51, or a fragment comprising at least 15, preferably 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 50 up to the maximum number of contiguous nucleotides of SEQ ED NO 51, said fragment characterized by the fact that it selectively hybridizes to the polynucleic acid consisting of SEQ ID NO 51. A polynucleic acid comprising SEQ ID NO 106, or a fragment consisting of at least 15, preferably 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 up to 50 contiguous nucleotides of said polynucleic acid, said fragment characterized by the fact that it selectively hybridizes to the polynucleic acid comprising SEQ ID NO 106. A polynucleic acid consisting of SEQ ID NO 106, or a fragment comprising at least 15, preferably 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 50 up to the maximum number of contiguous nucleotides of SEQ ID NO 106, said fragment characterized by the fact that it selectively hybridizes to the polynucleic acid consisting of SEQ ID NO 106. The invention further provides for a virus strain belonging to HIV-1 group O, comprising in its genome any of the above-mentioned nucleic acids. More particularly, the invention provides for a virus strain belonging to HIV-1 group O, comprising in its genome the RNA equivalent of - one of the DNA sequences represented by SEQ ID NO 1, SEQ ID NO 3, SEQ ID NO 5, SEQ ro NO 7, SEQ ro NO 9, SEQ ID NO 11, SEQ ro NO 13, SEQ ID NO 15, SEQ ro NO 17, SEQ ID NO 19, SEQ ro NO 21, SEQ ID NO 23, SEQ ID NO 25, SEQ ID NO 27, SEQ ro NO 29, SEQ ID NO 31, SEQ ID NO 33, SEQ ID NO 35, SEQ ro NO 37, SEQ ro NO 39, SEQ ro NO 106 and/or - one of the DNA sequences represented by SEQ ID NO 41 , SEQ ID NO 43, SEQ ID NO 45, SEQ ID NO 47, SEQ ID NO 49, SEQ ID NO 51, and/or - a variant sequence of the above-mentioned DNA sequences, said variant sequence showing at least 95% homology with the entire length of one of the above-mentioned sequences. More particularely, the invention relates to a strain of HIV-1 group O as defined above, comprising in its genome the RNA equivalent of the DNA sequence represented by SEQ ID NO 5 and/or SEQ ID NO 43 or a variant sequence thereof, said variant sequence showing at least 95% homology with SEQ ID NO 5 and/or SEQ ID NO 43. An HIV-1 group O strain of this type, termed FAB A (or synonymously MP331) has been deposited at the EC ACC on June 13 1997, under accession No V97061301. An example of a variant sequence of SEQ ID NO 5 is SEQ ID NO 7. The latter sequence was determined on a serum sample of a patient infected by the strain FAB A, while the former sequence was determined on peripheral blood mononuclear cells (PBMC's) taken from the same patient. The nucleic acids represented by SEQ ID NO 5 and SEQ ID NO 7 show 95% homology, and can be said to belong to strains from the same quasi-species. The invention also relates to a strain of HIV-1 group O as defined above, comprising in its genome the RNA equivalent of the DNA sequence represented by SEQ ID NO 9 and/or SEQ ID NO 45 or a variant sequence, said variant sequence showing at least 95% homology with SEQ ID NO 9 and/or SEQ ID NO 45. An fflV-1 group O strain of this type, termed MP450, has been deposited at the ECACC on June 13, 1997 under accession No. V97061302. An example of a variant sequence of SEQ ED NO 9 is SEQ ID NO 11. The latter sequence was determined on a serum sample of a patient infected by the strain MP450, while the former sequence was determined on peripheral blood mononuclear cells (PBMC's) taken from the same patient. Furthermore, the invention also relates to a strain of HIV-1 group O as defined above, comprising in its genome the RNA equivalent of the DNA sequence represented by SEQ ID NO 39 and/or SEQ ED NO 51 or a variant sequence, said variant sequence showing at least 95% homology with SEQ ED NO 39 and/or SEQ ID NO 51. An HIV-1 group O strain of this type, termed MP539, has been deposited at the ECACC on June 13, 1997 under accession NO.V97061303. Furthermore, the invention also relates to a strain of HIV-1 group O as defined above comprising in its genome the RNA equivalent of the DNA sequence represented by SEQ ED NO 1 and/or SEQ ID NO 41 or a variant sequence, said variant sequence showing at least 95% homology with SEQ ID NO 1 and/or SEQ ID NO 41. A strain of this type is termed MP340 throughout this invention. An example of a variant sequence of SEQ ID NO 1 is SEQ ID NO 3. The latter sequence was determined on a serum sample of a patient infected by the strain MP340, while the former sequence was determined on peripheral blood mononuclear cells (PBMC's) taken from the same patient. The nucleic acids represented by SEQ ID NO 1 and SEQ ID NO 3 show 99% homology, and can be said to belong to strains from the same quasi-species. Furthermore, the invention also relates to a strain of HIV-1 group O as defined above comprising in its genome the RNA equivalent of the DNA sequence represented by SEQ ID NO 13 and/or SEQ ID NO 47 or a variant sequence, said variant sequence showing at least 95% homology with SEQ ID NO 13 and/or SEQ ED NO 47. A strain of this type is termed MP448 throughout this invention. Furthermore, the invention also relates to a strain of HIV-1 group O as defined above comprising in its genome the RNA equivalent of the DNA sequence represented by SEQ ID NO 17 and/or SEQ ID NO 49 or a variant sequence, said variant sequence showing at least 95% homology with SEQ ID NO 17 and/or SEQ ID NO 49. A strain of this type is termed 189 throughout this invention. Furthermore, the invention also relates to a strain of HIV-1 group O as defined above comprising in its genome the RNA equivalent of the DNA sequence represented by SEQ ID NO 19 or a variant sequence showing at least 95% homology with SEQ ID NO 19. A strain of this type is termed 320 throughout this invention. Furthermore, the invention also relates to a strain of HIV-1 group O as defined above comprising in its genome the RNA equivalent of the DNA sequence represented by SEQ ID NO 21 or a variant sequence showing at least 95% homology with SEQ ED NO 21. A strain of this type is termed BSD422 throughout this invention. Furthermore, the invention also relates to a strain of HIV-1 group O as defined above comprising in its genome the RNA equivalent of the DNA sequence represented by SEQ ID NO 23 or a variant sequence showing at least 95% homology with SEQ ID NO 23. A strain of this type is termed KGT008 throughout this invention. Furthermore, the invention also relates to a strain of HIV-1 group O as defined above comprising in its genome the RNA equivalent of the DNA sequence represented by SEQ ID NO 25 or a variant sequence showing at least 95% homology with SEQ ID NO 25. A strain of this type, termed MP575, has been deposited at the ECACC on July 13, 1998, under provisional accession No. V98071301. Furthermore, the invention also relates to a strain of HIV-1 group O as defined above comprising in its genome the RNA equivalent of the DNA sequence represented by SEQ ID NO 27 or a variant sequence showing at least 95% homology with SEQ ID NO 27. A strain of this type is termed BSD 189 throughout this invention. Furthermore, the invention also relates to a strain of HIV-1 group O as defined above comprising in its genome the RNA equivalent of the DNA sequence represented by SEQ ID NO 29 or a variant sequence showing at least 95% homology with SEQ ED NO 29. A strain of this type is termed BSD649 throughout this invention. Furthermore, the invention also relates to a strain of HIV-1 group O as defined above comprising in its genome the RNA equivalent of the DNA sequence represented by SEQ ID NO 31 or a variant sequence showing at least 95% homology with SEQ ID NO 31. A strain of this type is termed BSD242 throughout this invention. Furthermore, the invention also relates to a strain of HIV-1 group O as defined above comprising in its genome the RNA equivalent of the DNA sequence represented by SEQ ID NO 33 or a variant sequence showing at least 95% homology with SEQ ID NO 33. A strain of this type is termed 533 throughout this invention. Furthermore, the invention also relates to a strain of HIV-1 group O as defined above comprising in its genome the RNA equivalent of the DNA sequence represented by SEQ ID NO 35 or a variant sequence showing at least 95% homology with SEQ ID NO 35. A strain of this type is termed 772. P94 throughout this invention. Furthermore, the invention also relates to a strain of HIV-1 group O as defined above comprising in its genome the RNA equivalent of the DNA sequence represented by SEQ ID NO 37 or a variant sequence showing at least 95% homology with SEQ ID NO 37. A strain of this type is termed MP95B throughout this invention. Furthermore, the invention also relates to a strain of HIV-1 group O as defined above comprising in its genome the RNA equivalent of the DNA sequence represented by SEQ ID NO 106 or a variant sequence showing at least 95% homology with SEQ ID NO 106. A strain of this type, termed MP645, has been deposited at the ECACC on July 13, 1998, under provisional accession No. V98071302 Another embodiment of the current invention provides for a nucleic acid molecule isolated from any of the E V-1 group O strains as defined above. In addition, the current invention provides for an antigen or antigen fragment isolated from any of the HIV-1 group O strains as defined above. It is to be understood that the current invention also provides for nucleic acid sequences and antigen sequences which are contained in the above-mentioned new HIV-1 group O viral strains, and which extend beyond the explicitly cited sequences represented by SEQ ID NO 1 to 102, 106, 135 to 138. The person skilled in the art will realize that, starting from the partial sequences disclosed above, it is perfectly possible to obtain the complete genomic information of the respective viruses, by standard cloning methods such as the construction of a cDNA library or the construction of a genomic library or by the technique of the polymerase chain reaction. Sometimes a combination of these methods may be necessary to obtain the sequence of the full genome. The following describes the strategies which may be followed to obtain additional genomic sequence information on HIV-1 group O strains, of which partial sequences have been disclosed above. 1. Construction of a cDNA library. HIV-1 group O viruses are propagated and isolated using standard methods e.g. by cultivation of peripheral blood lymphocytes (PBMC) from the HIV-infected individual together with stimulated lymphocytes from healthy donors, or alternatively by infecting cell lines with the virus in a permanent way. Once virus is detected in the culture supernatant using standard techniques (e.g. measuring reverse transcriptase activity; measuring p24 antigen...), virus is harvested from the culture supernantant by centrifugation under conditions where the virus is pelleted. RNA is obtained by disrupting the virus in a buffer containing 6M guanidinium chloride and the RNA is pelleted through a 5.5M CsCl cushion. The RNA which is resuspended in a suitable buffer is then phenolized and precipitated with e.g. ethanol and lithium chloride. cDNA synthesis is performed on the complete RNA or part of the RNA using commercially available kits. OligodT primers, random primers, or HIV-1 specific primers may be used to prime the cDNA synthesis which is done by a reverse transcriptase (RT) enzyme. This leads to a first DNA strand which is complementary to the initial RNA strand and which forms RNA::DNA hybrids. The RNA strand is removed with Rnase H and the second DNA strand is then synthesised with DNA polymerase I. The overhanging single stranded cDNA ends are removed with T4 DNA polymerase. The resulting cDNA is ligated to linkers which contain an appropriate restriction site. After hydrolysis of the cDNA with the appropriate restriction enzyme, the cDNA of suitable size is isolated (e.g. from agarose gel after electrophoresis) and ligated in a suitable vector. The vector containing the cDNA fragments can be propagated in competent E. coli cells using standard methods. Various techniques to screen for colonies containing HIV-1 specific sequences are known in the art. They involve screening of e.g. a cDNA expression library (e.g. λgtl l) with serum (polyclonal or monoclonal serum) or the screening of a cDNA library with 32 P labelled HIV-1 DNA fragments under non-stringent or stringent hybridization conditions. Background signals are lowered by washing the filters subsequently under more stringent conditions. After identification of the E. coli containing the suitable fragment, the fragment is isolated from the plasmid and is introduced (as a complete entity or a fragment thereof) in expression vectors. Using standard techniques, these vectors produce the protein(s) encoded by the inserted DNA fragment. The resulting proteins is further purified and used for the development of diagnostic assays. Sequence information of the virus is obtained from the plasmid containing viral DNA sequences. 2. Construction of a genomic library Chromosomal DNA is prepared from cells infected with the HIV-1 group O virus (e.g. cells permanently producing the virus) using standard techniques (Maniatis et al. 1982). This DNA may be used to construct a genomic library (Zabarousky and Allikmets 1986). The chromosomal DNA which contains the proviral HIV-1 group O DNA is partially digested with a selected restriction enzyme. Fragments between 9Kb and 23 Kb, isolated on a 40%- 10% sucrose gradient, are manipulated according to standard techniques in order to introduce them in a vector system suitable for the cloning of long DNA fragments e.g. lambda derived vectors or cosmids. The vector with the DNA fragment is introduced in a suitable E. coli strain and is further propagated onto plates. Plaques or colonies from the genomic library are transferred to nylon or nitrocellulose membranes and screened with enzyme or 32 P labelled DNA fragments of the viral genome (plaque or colony screening) under non-stringent or stringent hybridization conditions. Colonies or plaques displaying positive signals are purified from other colonies or plaques. The viral DNA is further subcloned and sequenced. Genes or fragments of genes are further manipulated using standard techniques in order to express important viral proteins or epitopes which may be used for the development of diagnostic assays. 3. Polymerase chain reaction (PCR). HIV-1 group O viral DNA fragments may also be obtained using the polymerase chain reaction (PCR) (Kwok et al. 1987) which is a standard technology used for the cloning of DNA fragments. PCR may be performed on cellular DNA of cells infected with the virus or on cDNA obtained from viral RNA derived from virus culture, lymphocytes, serum, plasma, .... The PCR may use primers which contain specific sequences of the virus based on sequences of the virus which are already known, or alternatively, primers which contain sequences derived from related viruses in regions known to be conserved or not conserved among HIV variants. Annealing conditions of the primers should preferentially not be too stringent (e.g. Tm -20°C), however the best conditions should be experimentally established. The resulting amplification product is subsequently sequenced and new primers are designed based on the newly generated sequence in order to further amplify the viral DNA, again eventually in combination with primers derived from the partially determined sequence of the isolate or from the sequence of related viruses. Example 4 provides the cloning and sequencing strategy followed in order to obtain the polynucleic acid sequences encoding the antigens Vif, Pol, Vpr, Tat (1st exon), Vpu, Rev (1st exon) and gplόO, or fragments thereof, from the HIV-1 group O viruses FAB A (MP331), MP448, MP539 and MP 645. Therefore, in addition to the gp41 and V3 sequences described above, the present invention further provides for a polynucleic acid containing a polynucleic acid sequence encoding at least part of the Vif, Pol, Vpr, Tat (1st exon), Vpu, Rev (1st exon) or gplόO antigens from any of the following HIV-1 group O strains of the invention: MP340, FABA(MP331), MP450, MP448, 189, MP539, 320, BSD422, KGT008, MP575, BSD189, BSD649, BSD242, 533, 772P94, MP95B and MP645. The terms "Vif, Pol, Vpr, Tat (1st exon), Vpu, Rev (1st exon) and gpl60" are terms for HIV-antigens familiar to the person skilled in the art. Vif and Vpu have important roles during virion morphogenesis. Vif is required for the production of fully infectious viruses, while Vpu is necessary for the efficient release of virus particles budding from the cell membrane in cultured cells (Gόttlinger et al, 1993). Vpu also mediates the rapid degradation of the CD4 receptor molecule in the endoplasmatic reticulum (Willey et al, 1992; Bour et al, 1995). The Vpr protein is involved in the nuclear migration of the prointegration complex (Heinzinger et al, 1994) and is also found in mature virions and hence a structural component of the virus (Paxton et al, 1993). Tat (transactivator) and Rev (regulator of virion expression) are encoded in overlapping reading frames which generate small regulatory proteins translated from multiple spliced mRNAs (Salfeld et al, 1990; Solomin et al, 1990; Furtado et al, 1991). Both proteins are essential for virus replication and are positive regulators of gene expression (Arya et al, 1985; Feinberg et al, 1986). Pol is encoded by the coding gene pol , which overlaps with the gag information but in a different reading frame. Pol is a precursor protein which is autocleaved to form the following viral enzymes: a protease, a reverse transcriptase with polymerase activity and Rnase H activity, and an integrase (Ross et al, 1991). Figure 8 illustrates the sequence of a large genomic fragment from a number of HIV-1 group O strains of the current invention (MP645 (SEQ ID NO 106), MP331 (SEQ ID NO 103), MP448 (SEQ ID NO 104) and MP539(SEQ ID NO 105)), and the location of the Vif, Pol, Vpr, Tat (1st exon), Vpu, Rev (1st exon) and gpl60 (partially) genes in these sequences. The present invention thus provides for a polynucleic acid comprising a nucleotide sequence chosen from the group of (I) a nucleotide sequence represented by any of SEQ ED NO 103, SEQ ID NO 104, SEQ ro NO 105, SEQ LD NO 106, or (ii) a nucleotide sequence complementary to a sequence according to (I), or (ϋi) a nucleotide sequence showing at least 95%, preferably 96%, 97%, 98% and most preferably 99% homology to a sequence according to (I), or (iv) a nucleotide sequence according to (I) whereby T is replaced by U, or (v) a nucleotide sequence according to (I) whereby at least one nucleotide is substituted by a nucleotide analogue, or (vi) a fragment a sequence of at least 15, preferably 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 up to 50 contiguous nucleotides of any of the nucleotide sequences according to (I) to (v), and characterized by the fact that it selectively hybridizes to the polynucleic acid from which it is derived, and/or selectively amplifies the polynucleic acid from which it is derived. More particularly, the present invention provides for a polynucleic acid consisting of a nucleotide sequence chosen from the group of (I) a nucleotide sequence represented by any of SEQ ro NO 103, SEQ ID NO 104, SEQ ro NO 105, SEQ ID NO 106, or (ii) a nucleotide sequence complementary to a sequence according to (I), or (ϋi) a nucleotide sequence showing at least 95%, preferably 96%, 97%, 98% and most preferably 99% homology to a sequence according to (I), or (iv) a nucleotide sequence according to (I) whereby T is replaced by U, or (v) a nucleotide sequence according to (I) whereby at least one nucleotide is substituted by a nucleotide analogue (vi) a fragment a sequence of at least 15, preferably 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 up to 50 contiguous nucleotides of any of the nucleotide sequences according to (I) to (v), and characterized by the fact that it selectively hybridizes to the polynucleic acid from which it is derived, and/or selectively amplifies the polynucleic acid from which it is derived. The above-described nucleic acid fragment may be used as a specific hybridization probe for the detection of the nucleic acids of the current invention. The term "selectively hybridizing" means that the hybridization signal obtained after hybridization of the fragment with the nucleic acid from which it is derived, is more intense than the hybridization signal obtained when the fragment is hybridized to the corresponding nucleic acid from another HIV-1 group O strain, under the same stringent hybridization and wash conditions. In practice this means that the nucleic acid fragment will show at least one mismatched nucleotide with the sequence of the corresponding nucleic acid fragment of another HIV- 1 group O strain. The term "stringent hybridization conditions" implies that the hybridization takes place at a temperature which is situated approximately between Tm and (Tm - 10°C), whereby Tm represents the calculated melting temperature of the target nucleic. It is generally known that the stringency depends on the percentage mismatches (=non-matching nucleotides upon alignment) present in the hybridizing duplex. According to a simplified formula, the hybridization temperature may be calculated as follows: Tm - 1.2 (% mismatch). A temperature decrease of 10°C implies a maximum percentage of allowed mismatches of 8.3%. The nucleic acid fragment as described above may also be used as a specific amplification primer of the nucleic acids of the current invention. The term "selective amplification" refers to the fact that said nucleic acid fragment may initiate a specific amplification reaction of the nucleic acids of the invention (e.g. a polymerase chain reaction) in the presence of other nucleic acids, under appropriate amplification conditions. It means that, under the appropriate amplification conditions, only the nucleic acids of the invention will be amplified, and not the other nucleic acids possibly present. Preferred embodiments of the invention comprise polynucleic acids or fragments thereof as specified below. A polynucleic acid comprising SEQ ID NO 103, or comprising a fragment consisting of at least 15, preferably 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, up to 50 contiguous nucleotides of said polynucleic acid, said fragment characterized by the fact that it selectively hybridizes to the polynucleic acid comprising SEQ ID NO 103. A polynucleic acid comprising SEQ ID NO 104, or comprising a fragment consisting of at least 15, preferably 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, up to 50 contiguous nucleotides of said polynucleic acid, said fragment characterized by the fact that it selectively hybridizes to the polynucleic acid comprising SEQ ID NO 104. A polynucleic acid comprising SEQ LD NO 105, or comprising a fragment consisting of at least 15, preferably 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, up to 50 contiguous nucleotides of said polynucleic acid, said fragment characterized by the fact that it selectively hybridizes to the polynucleic acid comprising SEQ LD NO 105. A polynucleic acid comprising SEQ LD NO 106, or comprising a fragment consisting of at least 15, preferably 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, up to 50 contiguous nucleotides of said polynucleic acid, said fragment characterized by the fact that it selectively hybridizes to the polynucleic acid comprising SEQ LD NO 106. Apolynucleic acid fragment consisting of a sequence of at least 15, preferably 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, up to 50 contiguous nucleotides of SEQ ID NO 103, said fragment characterized by the fact that it selectively amplifies the polynucleic acid from which it is derived. Apolynucleic acid fragment consisting of a sequence of at least 15, preferably 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, up to 50 contiguous nucleotides of SEQ ID NO 104, said fragment characterized by the fact that it selectively amplifies the polynucleic acid from which it is derived. Apolynucleic acid fragment consisting of a sequence of at least 15, preferably 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, up to 50 contiguous nucleotides of SEQ ED NO 105, said fragment characterized by the fact that it selectively amplifies the polynucleic acid from which it is derived. Apolynucleic acid fragment consisting of a sequence of at least 15, preferably 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, up to 50 contiguous nucleotides of SEQ ID NO 106, said fragment characterized by the fact that it selectively amplifies the polynucleic acid from which it is derived. The invention further provides for an antigen comprising at least part of Vif, Pol, Vpr, Tat (1st exon), Vpu, Rev (1st exon) and/or gplόO encoded by the nucleic acid sequences as described above from any of the following HIV-1 group O strains: MP340, FABA(MP331), MP450, MP448, 189, MP539, 320, BSD422, KGT008, MP575, BSD189, BSD649, BSD242, 533, 772P94, MP95B and MP645. The current invention more particularly provides for an antigen comprising at least one amino acid sequence chosen from the following groups of sequences Ii) an amino acid sequence represented by any of SEQ ED NO 107, SEQ ED NO 108, SEQ ID NO 109 and SEQ ID NO 110 representing the Vif antigen, (ii) an amino acid sequence represented by any of SEQ ID NO 111, SEQ ED NO 112, SEQ ID NO 113 and SEQ ID NO 114 representing the Vpu antigen, (ϋi) an amino acid sequence represented by any of SEQ ID NO 115, SEQ HD NO 116, SEQ ID NO 117 and SEQ ED NO 118 representing the Vpr antigen, (iv) an amino acid sequence represented by any of SEQ ID NO 119, SEQ ID NO 120, SEQ ID NO 121 and SEQ ID NO 122 representing the Tat antigen, (v) an amino acid sequence represented by any of SEQ ID NO 123, SEQ ED NO 124, SEQ ID NO 125 and SEQ ID NO 126 representing the Rev antigen, (vi) an amino acid sequence represented by any of SEQ ID NO 127, SEQ ED NO 128, SEQ ED NO 129 and SEQ ID NO 130 representing the Pol antigen, (vii) an amino acid sequence represented by any of SEQ ID NO 2, SEQ ID NO 4, SEQ ID NO 6, SEQ ro NO 8, SEQ ED NO 10, SEQ ID NO 12, SEQ ID NO 14, SEQ ID NO 16, SEQ ID NO 18, SEQ ID NO 20, SEQ ro NO 22, SEQ ID NO 24, SEQ ID NO 26, SEQ ID NO 28, SEQ ID NO 30, SEQ ID NO 32, SEQ ID NO 34, SEQ ID NO 36, SEQ ID NO 38, SEQ ID NO 40, SEQ ro NO 42, SEQ HD NO 44, SEQ ID NO 46, SEQ ID NO 48, SEQ ro NO 50, SEQ ID NO 52, SEQ ED NO 132, and SEQ ID NO 134 representing at least part of the Env antigen, or (viii) a fragment of any of the above-mentioned antigens Ii) to (vii), said fragment consisting of at least 8, preferably 9, 10, 11,12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 50 up to the maximum number of contiguous amino acids of the amino acid sequence of said antigen, and being characterized by the fact that it specifically reacts with antibodies raised against said antigen. The current invention further provides for an antigen consisting of an amino acid sequence chosen from the following groups of sequences: Ii) an amino acid sequence SEQ ID NO 107, SEQ ID NO 108, SEQ ID NO 109 and SEQ ID NO 110 representing the Vif antigen, (ϋ) an amino acid sequence SEQ ID NO 111, SEQ ID NO 112, SEQ ID NO 113 and SEQ ID NO 114 representing the Vpu antigen, (iii) an amino acid sequence SEQ ID NO 115, SEQ ID NO 116, SEQ ID NO 117 and SEQ ID NO 118 representing the Vpr antigen, (iv) an amino acid sequence SEQ ID NO 119, SEQ ID NO 120, SEQ ID NO 121 and SEQ ID NO 122 representing the Tat antigen, (v) an amino acid sequence SEQ ID NO 123, SEQ ID NO 124, SEQ ID NO 125 and SEQ ID NO 126 representing the Rev antigen, (vi) an amino acid sequence SEQ ID NO 127, SEQ ID NO 128, SEQ ID NO 129 and SEQ ID NO 130 representing the Pol antigen, (vii) an amino acid sequence represented by any of SEQ ID NO 2, SEQ ID NO 4, SEQ ED NO 6, SEQ ID NO 8, SEQ ID NO 10, SEQ ID NO 12, SEQ ID NO 14, SEQ ID NO 16, SEQ ID NO 18, SEQ ID NO 20, SEQ ID NO 22, SEQ ID NO 24, SEQ ID NO 26, SEQ ID NO 28, SEQ ID NO 30, SEQ HD NO 32, SEQ ro NO 34, SEQ ID NO 36,SEQ ID NO 38, SEQ ID NO 40, SEQ HD NO 42, SEQ ID NO 44, SEQ ID NO 46, SEQ ED NO 48, SEQ ID NO 50, SEQ ID NO 52, SEQ ED NO 132, and SEQ ED NO 134 representing at least part of the Env antigen, or (viϋ) a fragment of any of the above-mentioned antigens (I) to (vii), said fragment consisting of at least 8, preferably 9, 10, 11,12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 50 up to the maximum number of contiguous amino acids of the amino acid sequence of said antigen, and being characterized by the fact that it specifically reacts with antibodies raised against said antigen. The current invention thus also relates to: (I) an antigen derived from the gplόO env precursor protein of the new HIV-1 group 0 strain MP340 comprising at least one of the sequences according to SEQ ID NO 2, 4, 42,59, 60, 61, 73, 85, 86, 100, or fragments thereof with said fragments specifically reacting with antibodies raised against the antigen they are derived from; (ϋ) a polynucleic acid encoding an antigen according to (I) and comprising at least one of the nucleotide sequences according to SEQ ID NO 1, 3, 41, including homologous sequences, complementary sequences, and fragments hybridizing thereto; (iii) a virus strain comprising in its genome a polynucleic acid according to (ii), more particularly a virus strain termed MP340, as well as polynucleic acids and antigens isolated therefrom. The current invention thus also relates to: (I) an antigen derived from the gplόO env precursor protein of the new HIV-1 group 0 strain MP331 (or FAB A) comprising at least one of the sequences according to SEQ ID NO 6, 8, 44, 56, 57, 58, 82, 83, 84, 138 or fragments thereof with said fragments specifically reacting with antibodies raised against the antigen they are derived from; (ϋ) an antigen derived from the Vif, Vpu, Vpr, Tat, Rev, Pol and Env protein of the new HIV-1 group 0 strain MP331 (or FAB A) comprising at least one of the sequences according to SEQ ED NO 107, 111, 115, 119, 123, 127, 131, or fragments thereof with said fragments specifically reacting with antibodies raised against the antigen they are derived from; (iϋ) a polynucleic acid encoding an antigen according to (I) or (ii) and comprising at least one of the nucleic acid sequences according to SEQ ID NO 5, 7, 43, 103, including homologous sequences, complementary sequences, and fragments hybridizing thereto; (iv) a virus strain comprising in its genome said a polynucleic acid according to (iii), more particularly a virus strain termed MP331 (FAB A) deposited at the ECACC under accession number V97061301, as well as polynucleic acids and antigens isolated therefrom. The current invention thus also relates to: (I) an antigen derived from the gpl60 env precursor protein of the new HIV-1 group 0 strain MP450 comprising at least one of the sequences according to SEQ ID NO 10, 12, 46, 62, 63, 64, 73, 87, 100, or fragments thereof with said fragments specifically reacting with antibodies raised against the antigen they are derived from; (ii) a polynucleic acid encoding an antigen according to (I) and comprising at least one of the nucleotide sequences according to SEQ ID NO 9, 11, 45, including homologous sequences, complementary sequences, and fragments hybridizing thereto; (iii) a virus strain comprising in its genome a polynucleic acid according to (ii) , more particularly a virus strain termed MP450 deposited at the ECACC under accession number V97061302, as well as polynucleic acids and antigens isolated therefrom. The current invention thus also relates to: (I) an antigen derived from the gpl60 env precursor protein of the new HIV-1 group 0 strain MP448 comprising at least one of the sequences according to SEQ ID NO 14, 16, 48, 65, 66, 67, 76, 88, 101, or fragments thereof with said fragments specifically reacting with antibodies raised against the antigen they are derived from; (ϋ) an antigen derived from the Vif, Vpu, Vpr, Tat, Rev, Pol and Env protein of the new HIV-1 group 0 strain MP448 comprising at least one of the sequences according to SEQ ID NO 108. 112, 116, 120, 124, 128, 132 or fragments thereof with said fragments specifically reacting with antibodies raised against the antigen they are derived from; (ϋi) a polynucleic acid encoding an antigen according to (I) or (ii) and comprising at least one of the nucleic acid sequences according to SEQ ID NO 13, 15, 47, 104, including homologous sequences, complementary sequences, and fragments hybridizing thereto; (iv) A virus strain comprising in its genome said polynucleic acid according to (iii), more particularly a virus strain termed MP448, as well as polynucleic acids and antigens isolated therefrom. The current invention thus also relates to: (I) an antigen derived from the gplόO env precursor protein of the new HIV-1 group 0 strain 189 comprising at least one of the sequences according to SEQ ID NO 18, 50, 53, 54, 55, 73, 90, 91, or fragments thereof with said fragments specifically reacting with antibodies raised against the antigen they are derived from; (ii) a polynucleic acid encoding an antigen according to (I) and comprising at least one of the nucleotide sequences according to SEQ ID NO 17, 49, including homologous sequences, complementary sequences, and fragments hybridizing thereto; (iii) a virus strain comprising in its genome a polynucleic acid according to (ii), more particularly a virus strain termed 189, as well as polynucleic acids and antigens isolated therefrom. The current invention thus also relates to: (I) an antigen derived from the gplόO env precursor protein of the new HIV-1 group 0 strain MP539 comprising at least one of the sequences according to SEQ ID NO 40, 52, 68, 69, 70, 71, 89, 95 or fragments thereof with said fragments specifically reacting with antibodies raised against the antigen they are derived from; (ϋ) an antigen derived from the Vif, Vpu, Vpr, Tat, Rev, Pol and Env protein of the new HIV-1 group 0 strainMP539 comprising at least one of the sequences according to SEQ ED NO 109. 113, 117, 121, 125, 129, 133, or fragments thereof with said fragments specifically reacting with antibodies raised against the antigen they are derived from. (ϋi) a polynucleic acid encoding an antigen according to (I) or (ii) and comprising at least one of the nucleic acid sequences according to SEQ ID NO 39, 51, 105, including homologous sequences, complementary sequences, and fragments hybridizing thereto; (iv) A virus strain comprising in its genome said polynucleic acid according to (iii), more particularly a virus strain deposited at the ECACC under accession number V97061303, as well as polynucleic acids and antigens isolated therefrom. The current invention thus also relates to: (I) an antigen derived from the gplόO env precursor protein of the new HIV-1 group 0 strain 320 comprising at least one of the sequences according to SEQ ID NO 20, 92, or fragments thereof with said fragments specifically reacting with antibodies raised against the antigen they are derived from; (ii) a polynucleic acid encoding an antigen according to (I) and comprising the nucleotide sequence according to SEQ ID NO 19 including homologous sequences, complementary sequences, and fragments hybridizing thereto; (iii) a virus strain comprising in its genome a polynucleic acid according to (ii), more particularly a virus strain termed 320, as well as polynucleic acids and antigens isolated therefrom. The current invention thus also relates to: (I) an antigen derived from the gplόO env precursor protein of the new HIV-1 group 0 strain BSD422 comprising at least one of the sequences according to SEQ ID NO 22, 80, 79, or fragments thereof with said fragments specifically reacting with antibodies raised against the antigen they are derived from; (ϋ) a polynucleic acid encoding an antigen according to (I) and comprising the nucleotide sequence according to SEQ ID NO 21 including homologous sequences, complementary sequences, and fragments hybridizing thereto; (iii) a virus strain comprising in its genome a polynucleic acid according to (ii), more particularly a virus strain termed BSD422, as well as polynucleic acids and antigens isolated therefrom. The current invention thus also relates to: (I) an antigen derived from the gplόO env precursor protein of the new HIV-1 group 0 strain KGT008 comprising at least one of the sequences according to SEQ ED NO 24, 79, 99? or fragments thereof with said fragments specifically reacting with antibodies raised against the antigen they are derived from; (ϋ) a polynucleic acid encoding an antigen according to (I) and comprising the nucleotide sequence according to SEQ ID NO 23 including homologous sequences, complementary sequences, and fragments hybridizing thereto; (iii) a virus strain comprising in its genome a polynucleic acid according to (ii), more particularly a virus strain termed KGT008, as well as polynucleic acids and antigens isolated therefrom. The current invention thus also relates to: (I) an antigen derived from the gplόO env precursor protein of the new HIV-1 group 0 strain MP575 comprising the sequence according to SEQ ID NO 26, or fragments thereof with said fragments specifically reacting with antibodies raised against the antigen they are derived from; (ϋ) a polynucleic acid encoding an antigen according to Ii) and comprising the nucleotide sequence according to SEQ ID NO 25 including homologous sequences, complementary sequences, and fragments hybridizing thereto; (iii)A virus strain comprising in its genome said polynucleic acid according to (ii),more particularly a virus strain deposited at the ECACC under provisional accession number V98071301, as well as polynucleic acids and antigens isolated therefrom. The current invention thus also relates to: (I) an antigen derived from the gpl60 env precursor protein of the new HIV-1 group 0 strain BSD 189 comprising at least one of the sequences according to SEQ ID NO 28, 72, 95, or fragments thereof with said fragments specifically reacting with antibodies raised against the antigen they are derived from; (ϋ) a polynucleic acid encoding an antigen according to (I) and comprising the nucleotide sequence according to SEQ ID NO 27 including homologous sequences, complementary sequences, and fragments hybridizing thereto; (iii) a virus strain comprising in its genome a polynucleic acid according to (ii), more particularly a virus strain termed BSD 189, as well as polynucleic acids and antigens isolated therefrom. The current invention thus also relates to: (I) an antigen derived from the gplόO env precursor protein of the new HIV-1 group 0 strain BSD649 comprising at least one of the sequences according to SEQ ID NO 30, 77, 98, or fragments thereof with said fragments specifically reacting with antibodies raised against the antigen they are derived from; (ϋ) a polynucleic acid encoding an antigen according to (I) and comprising the nucleotide sequence according to SEQ ID NO 29 including homologous sequences, complementary sequences, and fragments hybridizing thereto; (iii) a virus strain comprising in its genome a polynucleic acid according to (ii), more particularly a virus strain termed BSD649, as well as polynucleic acids and antigens isolated therefrom. The current invention thus also relates to: (I) an antigen derived from the gplόO env precursor protein of the new HIV-1 group 0 stram BSD242 comprising at least one of the sequences according to SEQ ID NO 32, 81, 96, or fragments thereof with said fragments specifically reacting with antibodies raised against the antigen they are derived from; (ii) a polynucleic acid encoding an antigen according to (I) and comprising the nucleotide sequence according to SEQ ED NO 31 including homologous sequences, complementary sequences, and fragments hybridizing thereto; (iii) a virus strain comprising in its genome a polynucleic acid according to (ii), more particularly a virus strain termed BSD242, as well as polynucleic acids and antigens isolated therefrom. The current invention thus also relates to: (I) an antigen derived from the gplόO env precursor protein of the new HIV-1 group 0 strain 533 comprising at least one of the sequences according to SEQ ED NO 34, 81, 93, or fragments thereof with said fragments specifically reacting with antibodies raised against the antigen they are derived from; (ϋ) a polynucleic acid encoding an antigen according to (I) and comprising the nucleotide sequence according to SEQ ID NO 33 including homologous sequences, complementary sequences, and fragments hybridizing thereto; (iii) a virus strain comprising in its genome a polynucleic acid according to (ii), more particularly a virus strain termed 533, as well as polynucleic acids and antigens isolated therefrom. The current invention thus also relates to: (I) an antigen derived from the gplόO env precursor protein of the new HIV-1 group 0 strain 772P94 comprising at least one of the sequences according to SEQ ID NO 36, 75, 94, or fragments thereof with said fragments specifically reacting with antibodies raised against the antigen they are derived from; (ϋ) a polynucleic acid encoding an antigen according to (I) and comprising the nucleotide sequence according to SEQ ID NO 35 including homologous sequences, complementary sequences, and fragments hybridizing thereto; (iii) a virus strain comprising in its genome a polynucleic acid according to (ii), more particularly a virus strain termed 772P94, as well as polynucleic acids and antigens isolated therefrom. The current invention thus also relates to: (I) an antigen derived from the gplόO env precursor protein of the new HIV-1 group 0 strain MP95B comprising at least one of the sequences according to SEQ ID NO 38, 74, 102, or fragments thereof with said fragments specifically reacting with antibodies raised against the antigen they are derived from; (ϋ) a polynucleic acid encoding an antigen according to (I) and comprising the nucleotide sequence according to SEQ ED NO 37 including homologous sequences, complementary sequences, and fragments hybridizing thereto; (iii) a virus strain comprising in its genome a polynucleic acid according to (ii), more particularly a virus strain termed MP95B, as well as polynucleic acids and antigens isolated therefrom. The current invention thus also relates to: (I) an antigen derived from the gplόO env precursor protein of the new HIV-1 group 0 strain MP645 comprising at least one of the sequences according to SEQ ID NO 135, 136, 137, or fragments thereof with said fragments specifically reacting with antibodies raised against the antigen they are derived from; (ϋ) an antigen derived from the Vif, Vpu, Vpr, Tat, Rev, Pol and Env protein of the new HIV-1 group 0 strain MP645 comprising one of the sequences according to SEQ ID NO 110, Abo 114, 118, 122, 126,| 2θ| 134, or fragments thereof with said fragments specifically reacting with antibodies raised against the antigen they are derived from. (iii) a polynucleic acid encoding an antigen according to (I) or (ii) and comprising the nucleic acid sequence according to SEQ ID NO 106, including homologous sequences, complementary sequences, and fragments hybridizing thereto; (iv) A virus strain comprising in its genome said polynucleic acid according to (iii),more particularly a virus strain deposited at the ECACC under provisional accession number V98071302, as well as polynucleic acids and antigens isolated therefrom. In another embodiment, the invention provides for an antibody, preferably a monoclonal antibody, raised against an antigen or antigen fragment as described above. Such an antibody recognizes specifically the antigen or the antigen fragment to which it has been raised. According to an alternative embodiment, the present invention also relates to an antigen- binding fragment of the antibody, said fragment being of the F(ab') 2 , Fab or single chain Fv type, or any type of recombinant antibody derived from said specific antibodies or monoclonal antibodies, provided that said antibody fragment or recombinant antibody still recognizes specifically the antigen or antigen fragment to which it has been raised. The expression "antibody recognizing specifically" means that the binding between the antigen as a ligand and a molecule containing an antibody combining site, such as a Fab portion of a whole antibody, is specific, signifying that no cross-reaction occurs. The expression "antibody specifically raised against a compound" means that the sole immunogen used to produce said antibody was said compound. The possible cross-reactivity of polyclonal antisera may be eliminated by preabsorption of the polyclonal antiserum against the cross-reacting antigenic determinants. In a preferential embodiment, the above-mentioned antibodies are neutralizing antibodies, i.e. antibodies capable of in vitro inhibition of viral growth, determined according to methods known in the art. Neutralizing antibodies may be used as a reagent in a so-called "passive vaccine" composition, i.e. a composition conferring temporary protection against an infection, upon injection hi an individual. The invention also relates to passive vaccine compositions, comprising any of the above-mentioned neutralizing antibodies. The monoclonal antibodies of the invention can be produced by any hybridoma liable to be formed accordmg to classical methods from splenic cells of an animal, particularly of a mouse or rat, immunized with the antigen of the invention, defined above on the one hand, and of cells of a myeloma cell line on the other hand, and to be selected by the ability of the hybridoma to produce the monoclonal antibodies recognizing the antigen which has been initially used for the immunization of the animals. The monoclonal antibodies according to a preferred embodiment of the invention may be humanized versions of the mouse monoclonal antibodies made by means of recombinant DNA technology, departing from the mouse and/or human genomic DNA sequences coding for H and L chains or from cDNA clones coding for H and L chains. Also fragments derived from these monoclonal antibodies such as Fab, F(ab)' 2 and ssFv ("single chain variable fragment"), providing they have retained the original binding properties, form part of the present invention. Such fragments are commonly generated by, for instance, enzymatic digestion of the antibodies with papain, pepsin, or other proteases. It is well known to the person skilled in the art that monoclonal antibodies, or fragments thereof, can be modified for various uses. The antibodies involved in the invention can be labelled by an appropriate label of the enzymatic, fluorescent, or radioactive type. The invention also relates to the use of the antigens of the invention, or fragments thereof, for the selection of recombinant antibodies by the process of repertoire cloning (Perrson et al., 1991). The present invention further relates to an anti-idiotype antibody raised against any of the antibodies as defined above. The term "anti-idiotype antibodies" refers to monoclonal antibodies raised against the antigenic determinants of the variable region of monoclonal antibodies themselves raised against the antigens of the invention. These antigenic determinants of immunoglobulins are known as idiotypes (sets of idiotopes) and can therefore be considered to be the "fingerprint" of an antibody (for review see de Preval, 1978; Fleishmann and Davie,1984). The methods for production of monoclonal anti-idiotypic antibodies have been described by Gheuens and McFarlin (1982). Monoclonal anti-idiotypic antibodies have the property of forming an immunological complex with the idiotype of the monoclonal antibody against which they were raised. In this respect the monoclonal antibody is often referred to as Abl, and the anti-idiotypic antibody is referred to as Ab2. These anti-idiotype Ab2s may be used as substitutes for the polypeptides of the invention or as competitors for binding of the polypeptides of the invention to their target. The present invention further relates to antisense peptides derived from the antigens of the invention as described above. More particularly, the term "antisense peptide" is reviewed by Blalock (1990) and by Roubos (1990). In this respect, the molecular recognition theory (Blalock, 1990) states that not only the complementary nucleic acid sequences interact but that, in addition, interacting sites in proteins are composed of complementary amino acid sequences (sense ligand with receptor or sense ligand with antisense peptides). Thus, two peptides derived from complementary nucleic acid sequences in the same reading frame will show a total interchange of their hydrophobic and hydrophilic amino acids when the amino terminus of one is aligned with the carboxy terminus of the other. This inverted hydropathic pattern might allow two such peptides to assume complementary conformations responsible for specific interaction. The antisense peptides can be prepared as described in Ghiso et al. (1990). By means of this technology it is possible to logically construct a peptide having a physiologically relevant interaction with a known peptide by simple nucleotide sequence analysis for complementarity, and synthesize the peptide complementary to the binding site. The present invention further relates to a diagnostic method for detecting the presence of an HIV-1 infection, said method comprising - the detection of antibodies against HIV-1, including HIV-1 group O, using any of the antigens or antigen fragments of the invention as described above, and/or - the detection of viral antigen originating from HIV-1, including HIV-1 group O, using any of the antibodies of the invention as described above and/or - the detection of viral nucleic acids originating from HIV-1, including HIV-1 group O, using any of the nucleic acids or nucleic acid fragments of the invention as described above, in a biological sample. Preferably the above-mentioned diagnostic method for detecting the presence of an HIV-1 infection also includes the detection of an HIV-1 group O infection, and more particularly also includes the detection of an infection caused by any of the HIV-1 group O strains of the current invention. The term "biological sample" refers to any biological sample (tissue or fluid) possibly containing HIV nucleic acids, and/or HIV antigens and/or antibodies against HIV, and refers more particularly to blood, serum, plasma, organs or tissue samples. In most instances, the [HIV-1 group O]- reagents (=antigens and/or antibodies and/or nucleic acids) of the invention will be used in methods which combine them with other HIV- reagents (=antigens and/or antibodies and/or nucleic acids). The addition of the HIV-1 type O reagents of the current invention to methods and kits for detection of HIV-infection in general, may result in methods and kits showing - a higher sensitivity, and/or - a higher discriminating power between different types of HIV-infection, for example HIV-1 group M, HIV-1 group O and HIV-2 infection. The term "sensitivity" refers to the ratio of positively reacting samples/the number of truly infected samples. More specifically, the present invention relates to a method for in vitro diagnosis of a HTV-l infection, including a HIV-1 group O infection, comprising at least the step of contacting a biological sample with: a HTV-l group O antigen, or antigen fragment, as defined above, under conditions allowing the formation of an immunological complex, and/or, - a HTV-l group O nucleic acid, or nucleic acid fragment, as defined above, under conditions allowing the formation of a hybridization complex, with the nucleic acids of said sample being possibly amplified prior to hybridization, and/or, an antibody specifically directed against an HIV-1 group O antigen as defined above, under conditions allowing the formation of an immunological complex, and/or, an anti-idiotype antibody as defined above, under conditions allowing the formation of an antibody-anti-idiotypic complex, and/or, an antisense peptide as defined above, under conditions allowing the formation of an antigen-antisense peptide complex, and subsequently detecting the complexes formed. In a more specific embodiment, the invention relates to a method for detecting the presence of antibodies against HIV-1 in a biological sample, in particular antibodies against an HIV-1 group O strain, preferably a serum sample, comprising the following steps: - contacting the biological sample taken from a patient with at least one antigen or antigen fragment as described above, under conditions enabling the formation of an immunological complex, and - detecting the immunological complex formed between said antigen or antigen fragment and the antibodies possibly present in the sample. Conditions allowing the formation of an immunological complex are known to the person skilled in the art. In a special embodiment, the antigens being used in the above-described method for detection of anti-HIV-1 group O antibodies, can be replaced by anti-idiotype antibodies as described above, acting as their equivalents. Conditions allowing the formation of an antibody-anti-idiotypic complex are known in the art. The invention further relates to a method for detecting the presence of an antigen or an antigen fragment of HIV-1, in particular an antigen or antigen fragment of an HIV-1 group O strain, in a biological sample comprising the following steps: - contacting the biological sample taken from a patient with at least one antibody as described above under conditions enabling the formation of an immunological complex, and - detecting the immunological complex formed between said antibody and the antigen or antigen fragment possibly present in the sample. In a special embodiment, the antibodies being used in the above-described method for detection of HTV-l group O antigens, maybe replaced by anti-sense peptides as described above, acting as their equivalents. Conditions allowing the formation of an antigen-antisense peptide complex are known in the art. Design of immunoassays is subject to a great deal of variation, and many formats are known in the art. Protocols may, for example, use solid supports, or immunoprecipitation. Most assays involve the use of labelled antibody or polypeptide; the labels may be, for example, enzymatic, fluorescent, chemoluminescent, radioactive, or dye molecules. Assays which amplify the signals from the immune complex are also known, examples of which are assays which utilize biotin and avidin or streptavidin, and enzyme-labelled and mediated immunoassays, such as ELISA assays. An advantageous embodiment provides for a method for detection of anti-HIV-1 group O antibodies in a sample, whereby the antigens or antigen fragments of the invention are immobilized on a solid support, for example on a membrane strip. Different antigens or antigen fragments of the invention may be immobilized together or next to each other (e.g. in the form of parallel lines). The antigens of the invention may also be combined with other antigens, e.g. antigens from other HIV-1 group O strains, or from HIV-1 group M or from HIV-2 strains. The combination of different antigens in one single detection method as described above has certain advantages, such as: - achieving a higher test sensitivity: e.g. by combining several antigenic determinants from different HTV-strains, the total number of positively reacting sera originating from HIV-infected patients will be greater, and/or - enabling differentiation between individuals infected by different strains of HIV, more particularly enabling differentiation between HTV-l group M, HIV-1 group O and HIV-2 infected patients. The invention thus also relates to a solid support onto which the antigens of the invention, possibly in combination with other antigens, have been immobilized. Another embodiment of the invention provides for a method for detecting the presence of HIV-1 nucleic acids, including HIV-1 group O nucleic acids, in a biological sample, comprising: (I) possibly extracting the polynucleic acids contained in the sample, (ii) possibly amplifying the HIV-1 polynucleic acids, including the HIV-1 group O polynucleic acids, with a suitable primer pair, (iii) detecting the amplified nucleic acids, after hybridization with a probe as described above. The expression "a suitable primer pair" refers to a pair of primers allowing the amplification of the target region to which the probes of the current invention hybridize. Depending on the application, the primer sequences may be chosen such that they amplify specifically the nucleic acids of the current invention, or, on the other hand, it may be preferred to obtain a more general amplification, e.g. of all or nearly all HIV-1 group O sequences, or of all or nearly all HIV-1 sequences, and even HIV-2 sequences. In case a general amplification of HIV-1 group M and HIV-1 group O sequences is preferred, the following pair of primers may be used to amplify part of the gp41 region: 5'- GGGTTCTTGGGAGCAGCAGGAAGCACTATGGGCG-3' (SEQ ID NO 139), and 5'-TCTGAAACGACAGAGGTGAGTATCCCTGCCTAA-3' (SEQ ID NO 140)). In case a more specific amplification of the gp41 region of HIV-1 group O strains is preferred, the following pair of primers may be used: 5'-TGGATCCCACAGTGTACTGAAGGGTATAGTGCA-3' (SEQ ID NO 141), and 5'-CATTTAGTTATGTCAAGCCAATTCCAAA-3' (SEQ ID NO 142)). The invention also relates to a method for genotyping HIV-1 or HIV-1 type O strains, comprising the following steps: - possibly extracting the nucleic acids from the sample, - amplifying the HIV-1 or HIV-1 type O nucleic acids using a suitable primer pair, - hybridizing the nucleic acids of the sample with at least one probe as described above, - detecting the hybrids formed, - inferring the presence of one or more HIV-1 or HIV-1 type O genotypes from the hybridization pattern obtained. The term "genotyping" refers to the typing of HIV- strains according to the sequence of their nucleic acids. Depending on the application, it may be the intention of a genotyping assay to differentiate between large groups of HIV-strains (e.g. HIV-1 group M; HIV-1 group O or HIV-2) or to subtype smaller entities (such as e.g. the clades withing HIV-1 group M (A to J)). Subtyping within HTV-l group O may also be accomplished using the nucleic acids of the current invention. Conditions allowing hybridization are known in the art and e.g. exemplified in Maniatis et al. (1982). However, according to the hybridization solution (SSC, SSPE, etc.), the probes used should be hybridized at their appropriate temperature in order to attain sufficient specificity (in some cases differences at the level of one nucleotide mutation are to be discriminated). Amplification of nucleic acids present in a sample prior to detection in vitro may be accomplished by first extracting the nucleic acids present in the sample according to any of the techniques known in the art, and second, amplifying the target nucleic acid by any amplification method as specified above. In case of extraction of RNA, generation of cDNA is necessary; otherwise cDNA or genomic DNA is extracted. The term "labelled" refers to the use of labelled nucleic acids. This may include the use of labelled nucleotides incorporated during the polymerase step of the amplification such as illustrated by Saiki et al. (1988) or Bej et al. (1990) or labelled primers, or by any other method known to the person skilled in the art. Labels may be isotopic ( 32 P, 35 S, etc.) or non-isotopic (biotin, digoxigenin, etc.). Suitable assay methods for purposes of the present invention to detect hybrids formed between oligonucleotide probes according to the invention and the nucleic acid sequences in a sample may comprise any of the assay formats known in the art. For example, the detection can be accomplished using a dot blot format, the unlabelled amplified sample being bound to a membrane, the membrane being incubated with at least one labelled probe under suitable hybridization and wash conditions, and the presence of bound probe being monitored. Probes can be labelled with radioisotopes or with labels allowing chromogenic or chemiluminescent detection such as horse-radish peroxidase coupled probes. An alternative is a "reverse" dot-blot format, in which the amplified sequence contains a label. In this format, the unlabelled oligonucleotide probes are bound to a solid support and exposed to the labelled sample under appropriate stringent hybridization and subsequent washing conditions. It is to be understood that also any other assay method which relies on the formation of a hybrid between the nucleic acids of the sample and the oligonucleotide probes according to the present invention may be used. According to an advantageous embodiment, the process of detecting HIV-1 type O nucleic acids contained in a biological sample comprises the steps of contacting amplified copies of the nucleic acids present in the sample, with a solid support on which probes as defined above, have been previously immobilized. Preferably, the amplified nucleic acids are labelled in order to subsequently detect hybridization. In a very specific embodiment, the probes have been immobilized on a membrane strip in the form of parallel lines. This type of reverse hybridization method is specified further as a Line Probe Assay (LiPA), and has been described more extensively in for example WO 94/12670. The invention thus also relates to a solid support onto which the nucleic acids of the invention have been immobilized. The invention also provides for a composition comprising at least one of the antigens or antigen fragments as above described, and/or at least one of the nucleic acids or nucleic acid fragments as above described, and/or an antibody as above described. Examples of such compositions may be e.g. a diagnostic kit, an immunogenic composition, e.a. In particular, the invention provides for a kit for the detection of the presence of an HIV- 1 infection, comprising at least one of the antigens or antigen fragments as described above and/or at least one of the nucleic acids or nucleic acid fragments as described above and/or an antibody as described above. More specifically, the current invention provides for a diagnostic kit for determining the presence of HIV-1 nucleic acids, including HIV-1 type O nucleic acids, in a biological sample, said kit comprising at least one nucleic acid fragment as described above. This nucleic acid fragment may be used as a primer or a probe in said kit. In addition, the current invention provides for a kit for genotyping HIV-1 strains, including HTV-l type O strains, in a biological sample, said kit comprising at least one nucleic acid fragment as described above. This nucleic acid fragment may be used as a primer or a probe in said kit. Moreover, the present invention also provides for a kit for determining the presence of anti-(HTV-l type O) antibodies present in a biological sample, comprising at least one antigen or antigen fragment as described above. In addition , the present invention provides for a kit for determining the presence of HTV- 1 type O antigens present in a biological sample, comprising at least one antibody as described above. The current invention also provides for a vaccine composition which provides protective immunity against HIV-1 infection, in particular against HIV-1 group O infection, comprising as an active principle at least one antigen or antigen fragment as described above, or at least one nucleic acid as described above, or a virus like particle (VLP) comprising at least one antigen or antigen fragment as described above, or an attenuated form of at least one of the HJV-1 type O strains as described above, said active principle being combined with a pharmaceutically acceptable carrier. In a specific embodiment, polynucleic acid sequences coding for any of the antigens or antigen fragments as defined above, are used as a vaccine, either as naked DNA or as part of recombinant vectors. In this case, it is the aim that said nucleic acids are expressed into immunogenic protein / peptide and thus confer in vivo protection to the vaccinated host (e.g. Ulmer et al., 1993). The active ingredients of such a vaccine composition may be administered orally, subcutaneously, conjunctivally, intramuscularly, intra nasally, or via any other route known in the art including for instance via the binding to carriers, via incorporation into liposomes, by adding adjuvants known in the art, etc. FIGURE LEGEND Figure 1. Amino acid alignment of gp41 sequences from the HIV-1 group O strains of the current invention, compared to gp41 sequences from some known prototype HTV-l group O strains (Ant70, MVP5180, VAU: boxed). If the name of a strain is followed by -P or -PBMC, it means that the sequence was performed on strains present in peripheral blood monocytes samples, in stead of serum samples. Asteriks show perfectly conserved amino acids. Dots show well conserved amino acids. Dashes refer to gaps introduced to maximize the alignment. The immunodominant domain is underlined and within this domain the dashed line indicates the immunosuppressive peptide (ISU) and the dotted line indicates the principal immunodominant domain (PID) by analogy to HIV-1 group M viruses. The number of potential N-linked glycosylation sites which are shown by symbol A above the amino acid alignment, are indicated at the right of the sequences on figure l(contd. 1). Figure 2. Amino acid alignment of C2V3 sequences originating from some of the HIV-1 group O strains of the current invention (189, FABA, MP340, MP450, MP448, MP539), compared to C2V3 sequences from some known prototype HIV-1 group O strains (Ant70, MVP5180 and VAU: boxed). Asteriks show perfectly conserved amino acids. Dots show well conserved amino acids. Dashes refer to gaps introduced to maximize the alignment. The symbol + indicates the two conserved cysteine residues flanking the V3 loop region. Figure 3. Nucleic acid alignment of gp41 sequences originating from the HIV-1 group O strains of the current invention, compared to gp41 sequences from some known prototype HIV-1 group O strains (Ant70, MVP5180, VAU and VI686: in bold). Asteriks show positions of conserved nucleic acids. Dashes refer to gaps introduced to maximize alignment. Figure 4. Nucleic acid alignment of C2V3 sequences originating from some of the HIV-1 group O strains of the current invention (189, FABA MP340, MP448, MP450 and MP539), compared to C2V3 sequences from some known prototype HIV-1 group O strains (MVP5180, Ant70 and VI686: in bold). Asteriks show positions of conserved nucleic acids. Dashes refer to gaps introduced to maximize alignment. Figure 5. Phylogenetic tree analysis for the gp41-sequenced region of the new HIV-1 group O strains of the current invention, compared to the prototype HIV-1 group O strains (Ant70, MVP5180, VAU and VI686), HIV-1 group M strains (U455, Z2Z6 and MN), and SIVcpz- strains. SIVcpz-ANT has been used as an "outgroup" for the analysis, and is therefore put between brackets [J.The viruses of the current invention are indicated in bold. Country of origin is mentioned between parentheses. Phylogenetic relationships were determined using the neighbor joming method, as described in Materials and Methods. The numbers given at the branch points represent bootstrap values out of 100 obtained for the neigbor joining method. Figure 6. Nucleotide and amino acid sequences obtained from the new HIV-1 group O strains of the current invention. Figure 7. 7A. Comparison of the consensus amino acid sequences of the potential gp41 -immunosuppressive peptide (ISU) for HIV-1 group M and O strains and ISU-peptide for SIVcpzGAB and SIVcpzANT. 7B. Antigenicity/hydrophilicity plots of the consensus ISU-peptide (17 amino acids flanked by Leucine (L) residues) for HIV-1 group O and group M viruses. A value of 100% or nearly predicts the considered peptide to be highly immunogenic. Figure 8. 8 A. Nucleic acid sequence (SEQ ED NO 106) and the corresponding amino acid sequence translation of part of the genome of HIV-1 group O virus MP645. The corresponding λz\z> polypeptides Pol (partiallyX SEQ ID NOf*2θ}, Vif ( SEQ ID NO 110), Vpr ( SEQ ID NO 118), Tat ( SEQ ID NO 122), Rev ( SEQ ro NO 126), Vpu ( SEQ ID NO 114) and Env ( SEQ ID NO 134) (partially) are underlined and their corresponding name is indicated at the right of each open reading frame. 8B. Nucleic acid sequence (SEQ ID NO 103) and the corresponding amino acid sequence translation of part of the genome of HIV-1 group O virus MP331 (FABA). The corresponding polypeptides Pol (partially)(SEQ ID NO 127), Vif (SEQ ro NO 107), Vpr (SEQ ED NO 115), Tat (SEQ ED NO 119), Rev (SEQ ED NO 123), Vpu (SEQ ID NO 111) and Env (partially) (SEQ ID NO 131) are underlined and their corresponding name is indicated at the right of each open reading frame. 8C. Nucleic acid sequence (SEQ ID NO 104) and the corresponding amino acid sequence translation of part of the genome of HIV-1 group O virus MP448. The corresponding polypeptides Pol (partially) (SEQ ID NO 128), Vif (SEQ ID NO 108), Vpr (SEQ ID NO 116), Tat (SEQ ID NO 120), Rev (SEQ ID NO 124), Vpu (SEQ ID NO 112) and Env (partially) (SEQ ID NO 132) are underlined and their corresponding name is indicated at the right of each open reading frame. 8D. Nucleic acid sequence (SEQ ID NO 105) and the corresponding amino acid sequence translation of part of the genome of HIV-1 group O virus MP539. The corresponding polypeptides Pol (partially) (SEQ ID NO 129), Vif (SEQ ro NO 109), Vpr (SEQ ID NO 117), Tat (SEQ ID NO 121), Rev (SEQ ID NO 125), Vpu (SEQ ID NO 113) and Env (partially) (SEQ ED NO 133) are underlined and their corresponding name is indicated at the right of each open reading frame. TABLE LEGEND Table 1 : Divergence between HTV-l group M and O viruses and the chimpanzee viruses SIVcpzGAB and SIVcpzANT based on gp41 nucleic acid sequences. a : Divergence from group M viruses was calculated for at least three randomly selected strains for each of the subtypes from A to G. Table 2: Percent divergence (= 100% - % homology) between the gp41 nucleic acid sequences of the different HIV-1 group O strains of the current invention as specified in figure 3. Table l % genetic divergence Group O Group M CPZANT CPZGAB 37.5 (35.2-38.8) 31.2 (29.3-32.5) 32.6 CPZANT 36.5 (32.4-39.1) 33.7 (32.9-34.3) Group M 37.3 (35.0-40.8) 12.3 (2.2-16.6) Group O 14.7 (1.2-21.8) Table 2 (next page) ANT70 VP5180 VAU VI686 MP340 MP340 FABA FABA MP450 P450 MP448 MP448 189 320 BSD422 KGT008 PS75 BSD189 BSD649 BSD242 533 772P94 MP95B MP539 (PBMC) (PBMC) (PBMC) (PBMC) A T70 6 9 13 13 12 13 12 12 lo 9 14 9 9 11 7 9 6 22 23 19 15 18 MVP5180 .7 22 24 23 24 25 23 23 16 15 26 21 21 23 21 21 20 7 8 15 13 22 VAU 18 21 21 20 21 20 20 18 17 22 18 18 18 16 17 15 18 18 15 16 15 VI686 - 14 14 15 16 14 14 10 10 16 11 12 9 ' 10 10 10 26 25 22 15 18 MP340 (PBMC) - 1 14 15 2 2 14 14 2 14 15 17 13 11 12 26 24 20 20 20 MP340 13 12 2 2 15 15 2 14 14 17 13 11 12 27 24 20 20 19 FABA (PBMC) 5 13 13 15 15 13 14 18 17 13 14 13 28 26 20 20 22 FABA 13 13 15 15 15 15 18 17 14 14 14 29 27 20 20 22 MP450 (PBMC) 0 13 13 3 12 15 17 12 10 12 26 24 19 19 20 MP450 • 13 13 3 12 15 17 12 10 12 26 24 19 19 20 MP448 (PBMC) • 0 16 10 12 12 10 11 11 19 19 19 15 17 MP448 - 16 11 12 12 9 11 11 18 19 18 14 17 189 15 17 19 14 13 14 28 26 22 22 22 320 12 11 7 11 8 22 22 22 16 18 υ» BSD422 15 11 13 10 24 26 19 15 KGT008 10 12 12 26 26 22 19 20 MP575 8 7 25 25 20 17 17 BSD189 9 26 26 19 17 18 BSD649 24 23 19 16 18 BSD242 5 16 16 25 533 18 16 23 772P94 17 19 MP95B 18 MP539 EXAMPLES Example 1: Materials and methods Patients and viruses A total of 16 viruses have been characterized. Patients were identified as being infected with an HJV-1 group O virus using a specific serological testing algorithm, based on V3 peptides from different M and O strains (consensusM, M-Mal, O-ANT-70, O-VI686, O-MVP5180 (INNOLIA HIV-1 type O Research product, Innogenetics, Belgium), as described elsewhere (Peeters et al., in press). Ten patients were from Cameroon (BSD189, BSD242, BSD422, BSD649, MP340, MP95B, MP448, MP575, MP539 and MP450), 2 from Gabon (189, 533) and the others from Tchaad (320), Nigeria (KGT008), Senegal (FABA=331) and Niger (772P94). For 3 patients from Cameroon (MP340, MP448 and MP450) and for the patients from Nigeria and Senegal primary uncultured peripheral blood mononuclear cells (PBMCs) were available, while for the other patients from Cameroon, Gabon, Niger and Tchaad only serum was available. Strain VI686 from Gabon has been described previously (Janssens et al. 1994). Nucleic acid extraction DNA was extracted from PBMCs using the IsoQuick isolation kit (Microprobe Corp., Garden Cove, CA, USA), resuspended in the appropriate volume of nuclease free water and 1/10 was used for amplifications. Viral RNA was extracted from 50μl of plasma by the guanidinium thiocyanate-phenol-chloroform method as described previously by Chomczynsky and Sacchi (1987), resuspended in 5μl of nuclease free water and further used for reverse transcription reaction. RT. PCR and sequencing The reverse transcription reaction (RT) was performed in a final volume of 20 μl, containing 50 mM TrisHCl pH 8.3, 50 mM KC1, 10 mM MgCl 2 , 10 mM DTT, 0.5 mM spermidine, 1 mM each deoxynucleoside triphophate, 0.5 μM outer reverse primer (41-4, see further) and 5 U of Avian Myeloblastosis Virus Reverse Transcriptase (Promega), for 30 min at 42°C. Five microliters from the RT reaction were used for PCR amplification. Nested PCR was used to amplify a fragment of approximately 420bp from the gp41- region. Outer primers allow amplification of HIV-1 sequences from group O and M (sense 41-1 : 5'- GGGTTCTTGGGAGCAGCAGGAAGCACTATGGGCG-3' (SEQ ID NO 139), antisense 41-4: 5'-TCTGAAACGACAGAGGTGAGTATCCCTGCCTAA-3' (SEQ ID NO 140)). Inner primers were determined according to the HIV-l-Ant70 sequence (Vanden Haesevelde et al. 1994) (sense 41-6: 5'-TGGATCCCACAGTGTACTGAAGGGTATAGTGCA-3' (SEQ ID NO 141), antisense 41-7: 5'-CATTTAGTTATGTCAAGCCAATTCCAAA-3' (SEQ ED NO 142)). PCRs were performed in a final volume of 100 μl containing 10 mM Tris-HCl (pH 9.0), 50 mM KC1, 1.5 mM MgC12, 0.2 mM each deoxynucleoside triphosphate, 2.5 U of Taq DNA polymerase (Promega) and 0.4 μM of each primer. After an initial denaturation step of 3 min at 94°C, 30 to 35 cycles were performed at 94°C for lmin to 20 s, 50°C for 1 min to 30 s, 72°C for 1 min, followed by a final extension of 10 to 7 min. For the second round, 1 to 5 μl of the first amplification were subjected to the same cycling conditions for 35 to 40 PCR cycles. Amplification of the C2V3 -region was obtained by nested PCR using a set of primers selected from the HIV-l-Ant70 sequence. Outer primers were: anti-sense V70-5 (5'- GTTCTCCATATATCTTTCATATCTCCCCCTA-3', SEQ ID NO 143) and sense V70-1 (5'- TTGTACACATGGCATTAGGCCAACAGTAAGT-3', SEQ ro NO 144) and inner primers were: sense V70-2 (5'-TGAATTCCTAATATTGAATGGGACACTCTCT-3 « , SEQ ID NO 145) and antisense V70-4 (5'-TGGATCCTACAATAAAAGAATTCTCCATGACA-3', SEQ HD NO 146). Amplification conditions were as described above. Each fragment was sequenced on both strands, as previously described (Bibollet- Ruche 1997), using an Applied Biosystems sequencer (model 373 A, Applied Biosystems, Inc) and a dye-deoxy terminator procedure, as specified by the manufacturer. Sequence analysis Overlapping sequences were joined by using SeqEd-1.0 (Applied Biosystems, Inc). Sequences were aligned using CLUSTAL V (Higgins et al 1992; Higgins and Sharp 1988) program. Evolutionary distances were calculated by using the Kimura's two-parameters method with correction for the multiple substitutions and excluding positions with gaps in aligned sequences (Kimura 1983). Phylogenetic relationships were computed from the distance matrix by the neighbor-joining method (Saitou and Nei 1987). Phylogenetic analyses were also performed by a parsimony approach and implemented using DNAPARS. In both cases, reliability of the branching orders was confirmed by the bootstrap approach (Felsenstein 1985). Phylogenetic analyses were also performed for proteic sequences using PROTPARS. These methods were implemented using the PHYLIP 3.56 package (Felsenstein 1993). The results were similar with both methods, for nucleotidic and proteic sequences, in all essential aspects. Antigenicity profiles Antigenicity of the ISU peptides have been calculated according to programs developed by Gamier et al (1978) and Gibrat et al (1987). Example 2. Nucleic acid sequences and phylogenetic analysis Analysis of gp41 sequences For the 16 viruses, 330 to 351 bp of the region spanning the immunodominant domain of the transmembrane gp41 glycoprotein (by analogy to HIV-1 group M viruses) was characterized. The different sequences obtained are represented in figure 6. These sequences have been aligned to the corresponding gp41 -sequences of known HIV-1 group O strains, as shown in figure 3. Moreover, sequence identity was calculated for intra and intergroup similarity by pairwise alignment and comparison (Table 1). For the group M viruses, these values were calculated for randomly selected strains for which sequences were available in the database and which were representative of subtypes A to G (the same sequences were further used for phylogenetic analyses). Divergence between SIVcpz-GAB (Huet et al. 1990) and the group M (mean 31,2%) was lower than divergence between SIVcpz-GAB and the group O (mean 37%). These results were similar when calculated with the second chimpanzee virus, SIVcpz-ANT (Vanden Haesevelde et al. 1996), with mean divergence of 33.7% and 36.5% with group M and O respectively (Table 1). Intragroup divergence for group O viruses ranged from 1.2 to 21.8%o (mean 14.7%) while divergence within group M clades (A to G) ranged from 2.2 to 16.6% (mean 12.3%). Phylogenetic trees were constructed with the 16 new sequences described here, the four group O strains of which the gp41 sequences have already been characterized, nl. Ant70 (Vanden Haesevelde et al. 1994), MVP5180 (Gϋrtler et al. 1994), VAU (Charneau et al. 1994) and VI686 (Janssens et al. 1994) and group M viruses representative for A (U455), B (MN) and D (Z2Z6) subtypes (see figure 5). Trees were constructed from nucleotidic sequences according to the alignment in figure 3, by the neighbor-joining and by the maximum-parsimony methods. Consistent results were obtained by the two methods: group M and group O viruses clustered separately (bootstrap values 98 and 100 respectively). Within the newly characterized HJV-1 type O strains new subclusters may appear, such as for example the subcluster consisting of strains MP340, 189 and MP450, which segregate with a bootstrap value of 100, or the subcluster consisting of strains MVP5180, 533, BSD242 (bootstrap value 98). These subclusters may define different genotypes within group O in analogy to the different group M genotypes (clades). Phylogenetic analyses were also performed for the deduced amino acid sequences for group O and M viruses (data not shown) and the results were consistent with the nucleotidic sequences, although lower bootstrap values were observed (approximately 65%), probably due to the short size of the sequences (109 a.a., gaps excluded, data not shown). The countries from which these viruses were sampled are indicated alongside the strains and no links were found between the manner of clustering and the geographical origins of the strains. Table 2 shows the percentage divergence between gp41 -nucleotide sequences originating from HIV-1 group O strains of the invention and known HIV-1 group O strains (Ant70, MVP5180, VAU and VI686). Analysis of C2V3 sequences For 6 of the 16 new virus strains (189, FABA MP340, MP448, MP450 and MP539), C2V3 sequences were determined. Figure 4 shows the alignment of these new C2V3 sequences with the corresponding sequences of known HIV-1 group O strains. Example 3: Analysis of deduced amino acid sequences gp41 amino acid sequences Figure 1 depicts the alignment of the deduced gp41 amino acid sequences. Although different from group M, this region of the transmembrane glycoprotein is also highly conserved among group O viruses, especially for the region corresponding to the immunodominant region in group M isolates. This region has been divided into two domains, corresponding to an immunosuppressive peptide (ISU-peptide) of 17 amino acids (aa) and to an immunodominant cysteine loop of 7 aa (Oldstone et al. 1991), also called the principal immunodominant domain (PED). The consensus cysteine loop for group O viruses (CKGR/KLV/IC) is quite closely related to the group M consensus (CSGKLIC), suggesting that they could have similar functions in both virus groups. This PID sequence, corresponding to a B-cell epitope recognized by nearly all sera from patients or animals ( Bertoni et al. 1994; Chong et al. 1991; Gnann et al. 1987; Norrby et al. 1987; Pancino et al. 1993), seems to be a very conserved structure, in contrast to the variability observed for the neutralizing epitope of the V3 loop of HIV-1 gpl20 (Zwart et al. 1991; Zwart et al. 1993). Deletion of this PID peptide or disruption of the cysteine loop severely impairs the gpl60 processing, leading to a loss of infectivity in HIV-1 (Dedera et al. 1992; Pancino et al. 1993; Schulz et al. 1992) and also in the far related type D simian retrovirus (Brody and Hunter 1992). Comparison of ISU-peptides from the group M, SIVcpz and group O viruses are presented in figure 7A. The consensus peptide from group O is quite divergent from the SIVcpz/group M peptide by the presence of an arginine (R, positively charged) in position 2 instead of a phenylalanine (Q, hydrophilic), a leucine (L) in position 5 and 8 instead of a valine (V), and a very different stretch TLIQN instead of RYLKD in position 10-14. Prediction of the secondary structure revealed an alpha helix in each case, and the predicted isoelectric point is 9,7 and 11,3 for group M/SIVcpz and group O strains respectively. Figure 7B represents the predicted hydrophilicity/antigenicity plot and revealed the presence of a second peak at position 3 to 7 (ARLLA) for group O in addition to the peak at position 12 (L) conserved in group M/SIVcpz and group O viruses. The divergence of the ISU peptide between group O and M viruses may suggest different functionalities of the ISU peptide in both groups. For several retroviruses this ISU peptide has been shown to suppress a broad range of immune reactions such as the inhibition of IL-2-dependant and concanavaline A-induced proliferation of T lymphocytes (Denner et al. 1994; Ruegg et al. 1989) but also B lymphocyte proliferation for HIV-1 group M (Denner et al. 1996). The principal B-epitope of this ISU peptide has been mapped at the C-terminal end, centered around the leucine residue in position 12 for group M (Denner et al. 1994). The data of figure 7 show a similar antigenicity peak for group O viruses but, in contrast to group M and SIVcpz, the presence of a second peak is observed towards the N-terminal part of this peptide. Moreover, antibody response against this region in HIV-1 group M infected individuals has been shown to be vigorous and independent of the stage of the disease (Cumming et al. 1990; Zwart et al. 1994). This result raises the possibility fo the design of peptides for the specific detection of antibodies against group O viruses, which could improve the discrimination between the two HIV-1 groups, and could also be useful for the detection of divergent group O viruses given the high conservation of these peptides among the different strains we have characterized. A third interesting feature concerns the number and the position of the N-linked glycosylation sites in the immunodominant domain (Figure 1). In group M viruses, 4 sites are conserved in the gp41 extracellular domain and they have been shown to play important roles in the intracellular processing of the gplόO and in the fusogenic properties of gp41 (Dedera et al. 1992; Vanini et al. 1993). Most of the group O viruses described here contain only three potential N-linked glycosylation sites whereas only a few strains contain four. Only the position of the first site is highly conserved (position 60 in the alignment) and the positions of the two or three other sites vary among the strains, in contrast to group M viruses. In HIV-1 group M viruses, it is known that removal of the thirth glycosylation site abolishes the cleavage of the gplόO precursor and transport to the plasma membrane of infected cells. An immediate consequence of this result, obtained in vitro after transfection of this mutant in HeLa/CD4 cells, is that it fails to induce syncytia (Dash et al. 1994). Roles of the other N-linked glycosylation sites of the gp41 have not been fully explored but their high conservation suggests important functions. In the case of the gpl20, the highly conserved sites surrounding the V3 loop have been shown to influence infectivity (Lee et al. 1992), protein folding (Li et al. 1993) and immunogenicity (Benjouad et al 1992) of this domain. For group O viruses, only the first site is conserved in all the strains which were characterized. Even if the importance of N-glycosylation has not been studied for HIV-1 group O viruses, it can be speculated that differences will be observed when compared to group M viruses. In conclusion, comparison of the gp41 amino acid sequences clearly discriminate the two HIV-1 groups, either by the pattern of N-linked glycosylation sites or by the characteristics of the ISU peptide of the ectodomain of the transmembrane glycoprotein. The differences observed between the two HIV-1 groups in the gp41 region raise the possibility that these viruses use different mechanisms, for example in the intracellular processing of the envelope precursor or in the domains involved in the membrane fusion. Several studies have suggested that the immunodominant region of the gp41 in group M viruses, which is a target for neutralizing but also enhancing antibodies, could be a promising candidate for vaccine development (Cumming et al. 1990; Muster et al. 1993; Zwart et al. 1994). The data disclosed in the current invention suggest that a vaccine developed against HIV-1 group M viruses could be ineffective against group O strains, especially when these viruses could use different pathways to induce immunodeficiency in infected patients. Analysis of C2V3 amino acid sequences Figure 2 depicts the alignment of the deduced C2V3 sequences of 6 of the HIV-1 group O strains of the invention as compared to known HIV-1 group O strains. The delineation of the C2 and V3 region is according to Starcich et al. (1986) and Willey et al. (1986). The C2 region belongs to the rather conserved regions which are important in protein folding and protein function. The V3 region is one of the hypervariable regions, for which amino acid conservation between different HIV-1 isolates is below 50%. Hypervariable regions also contain short deletions or insertions (Myers et al. 1992). The V3 -region of gpl20, also known as the principal neutralizing determinant (PND), contains a loop of 35 amino acids, formed by a cysteine-cysteine disulfide bridge. The PND is implicated in several important biological functions, such as: 1. it determines the HIV-1 cell tropism (Hwang et al. 1991, Shioda et al. 1991) 2. it affects fusion (Feed et al. 1991) and viral virulence (Fouchier et al. 1992) 3. it stimulates cytotoxicity (Takahashi et al. 1992) 4. it is the primary target for antibody neutralization (Palker et al. 1989). The fact that the V3 domain of gpl20 may induce a protective immune response, has made this region of particular interest for vaccine research. Although the V3 region as a whole is hypervariable, there is a rather high sequence conservation in its tetrapeptide sequence Gly- Pro-Gly-Arg (GPGR) at the crown of the loop (LaRosa et al. 1990). This motif corresponds to the binding site of the neutralizing antibodies, and single amino acid changes within this epitope highly reduce antibody binding (Meloen et al. 1989). The alignment in figure 2 shows that sequence variability within the V3 loop is high between the different HIV-1 group O strains, including those of the current invention. These new sequences, and more particularly the sequences represented by SEQ ID NO 53 to 70 and SEQ ID NO 83 to 90 are important in the design of new and better (= more sensitive and/or more specific) HIV-diagnostic assays. Moreover, the various sequences in the V3 region will be important with regard to the development of HJV-vaccines providing an as broad as possible protection against HIV-infection. Example 4: Cloning strategy to obtain Vif. Vpu. Vpr. Tat. Rev. Env and Pol. Polymerase chain reaction amplification and sequencing The sequences of the nested primer sets were designed on HIV-1 nucleic acid sequences in conserved regions flanking the Vif and Vpu genes. DNA from cultured and uncultured PBMCs was extracted using IsoQuick (Microprobe, Garden Cove, CA) according to the manufacturer instructions and quantified spectrophotometrically. Approximately 1 μg of DNA was used for a first round of amplification with an outer primer pair (VT 1, 5' GGGTTTATTACAGGGACAGCAGAG 3' (SEQ ID NO 147) and VPU1, 5' GGTTGGGGTCTGTGGGTACACAGG 3') (SEQ ID NO 148) in a final volume of 100 μl of containing 10 mM Tris-HCl (pH 9.0), 50 mM KCl, 1.5 mM MgCl 2 a 0.2 mM concentration of each deoxynucleoside triphosphate, 2.5 U of Taq DNA polymerase (Promega, Madison, WI), and a 0.4 μM concentration of each primer. Five microliters from this first round was used for a second round with an inner primer pair (VIF2, 5' GCAAAACTACTCTGGAAAGGTG 3' (SEQ HD NO 149) and VPU2, 5' GCWTCTTTCCACACAGGTACCCC 3' (SEQ ID NO 150) where W represents an A or a T) under the same reaction conditions. The two rounds of PCR were run for 35 cycles each under the following cycling conditions:94°C for 30 sec, 50 °C for 30 sec, and 72 °C for 2 min. The two rounds of PCR were preceded by a denaturation step of 3 min at 94 °C and followed by a final extension step of 7 min at 72 ° C. Sequencing of the amplified products was done directly after purification by TAE-low melting point agarose gel electrophoresis (Bibollet-Ruche et al, 1997) using an Applied Biosystems (Foster City, CA) 373 Stretch sequencer and a Dye-Deoxy terminator procedure (dye terminator cycle sequencing ready reaction, with AmpliTaq DNA polymerase; Perkin-Elmer. Norwalk, CT) as specified by the manufacturer. Inner polymerase chain reaction (PCR) primers (\TF2 and VPU2) and inner sequencing primers (OVIF, 5' CATATTGGGGATTGATGCCAG 3' (SEQ ID NO 151); OVPU, 5'GCATYAGCGTTACTTACTGC 3': Y= C or T (SEQ ID NO 152)) were used. Overlapping sequences were joined using SeqEd (Applied Biosystems) to obtain the full-length sequence. Direct sequencing was performed on PCR-generated fragments. Ambiguities observed at a limited number of positions in some sequences were resolved when joining the overlapping fragments. Analyses of accessory protein sequences Open reading frames for the different accessory proteins (Pol, Vif, Vpr, the first exon of Tat, Vpu and Env) were determined and the deduced protein sequences were obtained using the Translate program option of the PCgene software package. The resulting sequences are indicated in figure 8 (B to D). Figure 8 A shows the sequences of HIV-1 group O strain MP645 which was obtained following a similar approach as the one described above for MP448, MP539 and MP331. REFERENCES Agarwal et al. 1972. Agnew. Chem. Int. Ed. Engl. 11: 451. Arya, S., et al. 1985. Trans-activator gene of the human T-lymphotropic virus type III (HTLV-III). Science 229: 69-73. Asseline U, Delarue M, Lancelot G, Toulme F, Thuong N (1984) Nucleic acid-binding molecules with high affinity and base sequence specificity : intercalating agents covalently linked to oligodeoxynucleotides. Proc. Natl. Acad. Sci. USA 81(11):3297-301. Baeucage et al. 1981. Tetrahedron Letters 22: 1859-1862. Barany F (1991) Genetic disease detection and DNA amplification using cloned thermostable ligase. Proc. Natl. Acad. Sci USA 88: 189-193. Barre-Sinoussi et al. 1983. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220:868-871. Bej A, Mahbubani M, Miller R, Di Cesare J, Haff L, Atlas R ( 1990) Multiplex PCR amplification and immobilized capture probes for detection of bacterial pathogens and indicators in water. Mol Cell Probes 4:353-365. Benjouad, A., J.-C. Gluckman, H. Rochat, L. Montagnier, and E. Bahraoui. 1992. Influence of carbohydrate moieties on the immunogenicity of human immunodeficiency virus type 1 recombinant gp 160. J. Virol. 66:2473-2483. Bertoni, G, M.-L. Zahno, R. Zanoni, H.-R. Vogt, E. Peterhans, G. Ruff, W. P. Cheevers, P. Sonigo, and G. Pancino. 1994. Antibody reactivity to the immunodominant epitopes of the caprine arthritis-encephalitis virus gp38 transmembrane glycoprotein associates with the development of arthritis. J. Virol. 68:7139-7147. Bibollet-Ruche, F., C. Brengues, A. Galat-Luong, G. Galat, X. Pourrut, N. Vidal, F. Veas, J.-P. Durand, and G. Cuny. 1997. Genetic diversity of simian immunodeficiency viruses from west african green monkeys: evidence for multiple genotypes within populations from the same geographical locale. J. Virol. 71:307-313. Blalock J (1990) Complementarity of peptides specified by 'sense' and 'antisense' strands of DNA. Trends Biotechnol. 8: 140-144. Bour, S., et al. 1995. The human immunodeficiency virus type 1 Vpu protein specifically binds to the cytoplasmic domein of CD4: implication for the mechanism of degradation. J. Virol. 69: 1510-1520. Braaten, D., E. K. Franke, and J. Luban. 1996. Cyclophilin A is required for the replication of group M human immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus SIVcpzGAB but not group O HIV-1 or other primate immunodeficiency viruses. J. Virol. 70:4220-4227. Brody, B. A., and E. Hunter. 1992. Mutations within the env gene of Mazon-Pfizer monkey virus: effects on protein transport and SU-TM association. J. Virol. 66:3466-3475. Centers for Disease Control and Prevention. 1996. Identification of HIV-1 group O infection, Los Angeles County, California. MMWR 45:561-564. Charneau, P., A. M. Borman, C. Quillent, D. Guetard, S. Chamaret, J. Cohen, G. Remy, L. Montagnier, and F. Clavel. 1994. Isolation and envelope sequence of a highly divergent HIV-1 isolate: definition of a new HIV-1 group. Virology 205:247-253. Chomczynsky, P., and N. Sacchi. 1987. Single step method of RNA isolation by guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162: 156-159. Chong, Y.-H., J. M. Ball, C. J. Issel, R. C. Montelaro, and K. E. Rushlow. 1991. Analysis of equine humoral responses to the transmembrane envelope glycoprotein (gp45) of equine anemia virus. J. Virol. 65:1013-1018. Clavel et al. 1986, Molecular cloning and polymorphism of the HIV-type 2. Nature (London) 324: 691-694. Clavel et al. 1986, Isolation of a new human retrovirus from West African patients with AIDS. Science 233:343-346. Compton J (1991). Nucleic acid sequence-based amplification. Nature, 350: 91-92. Cumming, S. A., D. A. McPhee, W. J. Maskill, B. E. Kemp, R. R. Doherty, and I .D. Gust. 1990. Use of conserved immunodominant epitope of HIV surface glycoprotein gp41 in the detection of early antibodies. AIDS 4:83-86. Dash, B., A. Mclntosh, W. Barrett, and R. Daniels. 1994. Deletion of a single N-linked glycosylation site from the transmembrane envelope protein of human immunodeficiency virus type 1 stops cleavage and transport of gplόO preventing env-mediated fusion. J. Gen. Virol. 75:1389-1397. de Preval (1978) Immunoglobulins, In: Bach J Immunology, New York, Wiley and Sons: 144- 219. De Leys, R., B. Vanderborght, M. Vanden Haesevelde, L. Heyndrickx, A. van Geel, C. Wauters, R. Bernaerts, E. Saman, P. Nijs, B. Willems, H. Taelman, G. van der Groen, P. Piot, T. Tersmette, J. G. Huisman, and H. Van Heuverswyn. 1990. Isolation and partial characterization of an unusual human immunodeficiency retrovirus from two persons of West-Central African origin. J. Virol. 64:1207-1216. Dedera, D., R. Gu, and L. Ratner. 1992. Conserved cystein residues in the human immunodeficiency virus type 1 transmembrane envelope protein are essential for precursor envelope cleavage. J. Virol. 66:1207-1209. Denner, J., S. Norley, and R. Kurth. 1994. The immunosuppressive peptide of HIV-1 : functional domains and immune response in AIDS patients. AIDS 8: 1063-1072. Denner, J., C. Persin, T. Vogel, D. Haustein, S. Norley, and R. Kurth. 1996. The immunosuppressive peptide of HIV-1 inhibits T and B lymphocyte stimulation. J. AIDS and Hum. Ret. 12:442-450. Duck P (1990). Probe amplifier system based on chimeric cycling oligonucleotides. Biotechniques 9, 142-147. Feinberg, M., et al. 1986. HTLVIII expression and production involve complex regulation at the levels of splicing and translation of viral RNA. Cell 46: 807-817. Felsenstein, J. 1985. Confidence limits on phylogenies: an approach using the bootstrap. Evolution 39: 783-791. Felsenstein, J. 1993. PHYLEP (phylogeny interference package) version 3.5c. Department of Genetics, University of Washington, Seattle. Fleishmann J, Davie J (1984) Immunoglobulins: allotypes and idiotypes. In: Paul W (Ed) Fundamental Immunology. New York, Raven Press: 205-220. Furtado, M., et al. 1991. Analysis of alternatively spliced human immunodeficiency virus type 1 mRNA species, one of which encodes a novel tat-env fusion protein. Virology 185: 258-270. Gallo et al. 1984. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science 224, 500-503. Gao, F., S. G. Morrison, D. L. Robertson, C. L. Thornton, S. Craig, G. Karlsson, J. Sodroski, M. Morgado, B. Galvao-Castro, H. von Briesen, S. Beddows, J. Weber, P. M. Shaφ, G. M. Shaw, B. H. Hahn, and the WHO and NIAID networks for HIV isolation and characterization. Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. J. Virol. 70:1651-1667. Gamier, J., D. J. Osguthorpe, and B Robson. 1978. Analysis of the accuracy and implication of simple methods for predicting the secondary structure of globular proteins. J. Mol. Biol. 120:97-120. Gheuens J, Mc Farlin D (1982) Use of monoclonal anti-idiotypic antibody to P3-X6Ag8 myeloma protein for analysis and purification of B lymphocyte hybridoma products. Eur J Immunol 12: 701-703. Ghiso J, Saball E, Leoni J, Rostagno Frangion (1990) Binding of cystatin C to C4: the importance of antisense peptides and their interaction. Proc Natl Acad Sci (USA) 87: 1288- 1291. Gibrat, J. F., J. Gamier, and B. Robson. 1987. Further development of protein secondary structure prediction using information theory. New parameters ans consideration of residue pairs. J. Mol. Biol. 198:425-443. Gnann, J. W., J. A. Nelson, and M. B. A. Oldstone. 1987. Fine mapping of an immunodominant domain in the transmembrane glycoprotein of human immunodeficiency virus. J. Virol. 61:2639-2641. Gόttlinger, H. G, et al. 1993. Vpu protein of human immunodeficiency virus type 1 enhances the release of capsids produced by gag gene constructs of widely divergent retroviruses. Proc. Natl. Acad. Sci. USA 90: 7381-7385. Guatelli J, Whitfield K, Kwoh D, Barringer K, Richman D, Gengeras T (1990) Isothermal, in vitro amplification of nucleic acids by a multienzyme reaction modeled after retroviral replication. Proc Natl Acad Sci USA 87: 1874-1878. Gurtler, L. G, P. H. Hauser, J. Eberle, A. von Brunn, S. Knapp, L. Zekeng, J. M. Tsague, and L. Kaptue. 1994. A new subtype of human immunodeficiency virus type 1 (MVP-5180) from Cameroon. J. Virol. 68: 1581-1585. Hampl, H., D. Sawitzky, M. Stόfϊler-Meilicke, A. Groh, M. Schmitt, J. Eberle, and L. Gurtler. 1995. First case of HIV-1 subtype O infection in Germany. Infection 6:369-370. Heinzinger, N. K. et al. 1994. The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells. Proc. Natl. Acad. Sci. 91: 7311-7315. Higgins, D. G., A. J. Bleasby, and R. Fuchs. 1992. CLUSTAL V: improved software for multiple sequence alignment. Comp. Appl. Biosci. 8:189-191. Higgins, D. G., and P. M. Sharp. 1988. CLUSTAL: a package for performing multiple sequence alignment on a microcomputer. Gene 73:237-244. Hsiung et al. 1979. Nucleic Acid Res. 6:1371. Huet, T., R. Cheyier, A. Meyerhans, G. Roelants, and S. Wain-Hobson. 1990. Genetic organisation of a chimpanzee lentivirus related to HIV-1. Nature (London) 345:356-358. Janssens, W., J. N. Nkengasong, L. Heyndrickx, K. Fransen, P. M. Ndumbe, E. Delaporte, M. Peeters, J.-L. Perret, A. Ndoumou, C. Atende, P. Piot, and G Van der Groen. 1994. Further evidence of the presence of genetically aberrant strains in Cameroon and Gabon. AIDS 8:1012-1013. Javaherian K, Langlois A McDanal C et al. 1989. Principal neutralizing domain of human immunodeficiency virus type I envelope glycoprotein. Proc Natl Acad Sci USA 86: 5768- 5772. Kimura, M. 1983. The neutral theory of molecular evolution. Cambridge University Press, Cambridge, United Kingdom. Kostrikis, L. G, E. Bagdades, Y. Cao, L. Zhang, D. Dimitriou, and D. D. Ho. 1995. Genetic analysis of human immunodeficiency type 1 strains from patients in Cyprus: identification of a new subtype designated subtype I. J. Virol. 69:6122-6130. Kwoh D, Davis G, Whitfield K, Chappelle H, Dimichele L, Gingeras T (1989). Transcription- based amplification system and detection of amplified human immunodeficiency virus type 1 with a bead-based sandwich hybridization format. Proc Natl Acad Sci USA, 86: 1173-1177. Kwok S, Kellogg D, McKinney N, Spasic D, Goda L, Levenson C, Sinisky J, (1990). Effects of primer-template mismatches on the polymerase chain reaction: Human immunodeficiency views type 1 model studies. Nucl. Acids Res., 18: 999. Kwok S, MackD H, MullisKB et al. (1987) Identification of human immunodeficiency virus sequences by using in vitro enzymatic amplification and oligomer cleavage detection. J. Virology, 61: 1690-1694. Landgren U, Kaiser R, Sanders J, Hood L (1988). A ligase-mediated gene detection technique. Science 241 :1077-1080. Lee, W. R., W. Syu, B. Du, M. Matsuda, S. Tan, A. Wolf, M. Essex, and T. Lee. 1992. Non-random distribution of gpl20 N-linked glycosylation sites important for infectivity of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA 89:2213-2217. Leonard C, Spellman M, Riddle L et al. 1990. Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of hte type 1 recombinant human immunodeficiency vims envelope glycoprotein (gpl20) expressed in Chinese hamster ovary cells. J Biol Chem 265: 10373-10382. Li, Y., L. Luo, N. Rasool, and C. Y. Kang. 1993. Glycosylation is necessary for the correct folding of human immunodeficiency vims gpl20 in CD4 binding. J. Virol. 67:584-588. Lizardi P, Guerra C, Lomeli H, Tussie luna I, Kramer F. 1988. Exponential amplification of recombiannt RNA hybridization probes. Bio/Technology 6: 1197-1202. Lomeli H, Tyagi S, Printchard C, Lisardi P, Kramer F (1989) Quantitative assays based on the use of replicatable hybridization probes. Clin Chem 35: 1826-1831. Loussert-Ajaka, I, T. D. Ly, M.-L. Chaix, D. Ingrand, S. Saragosti, A. M. Courouce, F. Brun-Vezinet, and F. Simon. 1994. HIV-1 /HIV-2 seronegativity in HIV-1 subtype O infected patients. Lancet 343:1393-1394. Loussert-Ajaka, I., M.-L. Chaix, B. Korber, F. Letourneur, E. Gomas, E. Allen, T.-D. Ly, F. Brun-Vezinet, F. Simon, and S. Saragosti. 1995. Variability of human immunodeficiency vims group O strains isolated from Cameroonian patients living in France. J. Virol. 69:5640-5649. Louwagie J. , F. McCutchan, M. Peeters, T. P. Brenan, E. Sanders-Buell, G A. Eddy, G. van der Groen, K. Fransen, G.-M. Gershy-Damet, R. Deleys, and D. S. Burke. 1993. Phylogenetic analysis of gag genes from 70 international HIV-1 isolates provides evidence of multiple genotypes. AIDS 7:769-780. Maniatis, T., E.F. Fritsch, and J. Sambrook. 1982. Molecular cloning. A laboratory manuel. Cold Spring Harbor Laboratory, Cold Spring Harbor, N. Y. Matsukura M, Shinozuka K, Zon G, Mitsuya H, Reitz M, Cohen J, Broder S (1987) Phosphorothioate analogs of oligodeoxynucleotides : inhibitors of replication and cytopathic effects of human immunodeficiency vims. Proc. Natl. Acad. Sci. USA 84(21):7706-10. May, R. M., and R. M. Anderson. 1990. Parasite-host co-evolution. Parasitology 100 (suppl):S89-S101. Miller P, Yano J, Yano E, Carroll C, Jayaram K, Ts'o P (1979) Nonionic nucleic acid analogues. Synthesis and characterization of dideoxyribonucleoside methylphosphonates. Biochemistry 18(23):5134-43. Monell, C. R., D. R. Hoover, N. Odaka, X. He, A. J. Saah, and M. Strand. 1993. Assessement of the antibody response to the immunosuppressive/immunodominant region of HIV gp41 in a 5-year longitudinal study. J. Med. Virol. 39: 125-130. Muster, T., F. Steindl, M. Purtscher, A. Trkola, A. Klima, G. Himmler, F. Ruker, and H. Katinger. 1993. A conserved neutralizing epitope on gp41 of human immunodeficiency vims type 1. J. Virol. 67:6642-6647. Myers, G, B. Korber, B. H. Hahn, K.-T. Jeang, J. W. Mellors, F. E. McCutchan; L. E. Henderson, and G. N. Pavlakis (Eds.). 1995. Human Retrovimses and AIDS : a compilation and analysis of nucleic acid and amino acid sequences. Theorical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, N. Mex. Nielsen P, Egholm M, Berg R, Buchardt O (1991) Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. Science 254(5037): 1497-500. Nielsen P, Egholm M, Berg R, Buchardt O (1993) Sequence specific inhibition of DNA restriction enzyme cleavage by PNA. Nucleic-Acids-Res. 21(2): 197-200. Nkengasong, J. N., M. Peeteers, M. Vanden Haesevelde, S. S. Musi, B. Willems, P. M. Ndumbe, E. Delaporte, J. L. Perret, P. Piot, ad G. Van der Groen. 1993. Antigenic evidence of the presence of the aberrant HIV-1 ANT70 vims in Cameroon and Gabon. AIDS 7:1536-1538. Norrby, E., G. Biberfeld, F. Chiodi, A. von Gegerfeldt, A. Naucler, E. Parks, and R. Lerner. 1987. Discrimination between antibodies to HIV and to related retrovimses using site-directed serology. Nature (London) 329:248-250. Oldstone, M. B., A. Tishon, H. Lewicki, H. J. Dyson, V. A. Feher, N. Assa-Munt, and P. E. Wright. 1991. Mapping of the anatomy of the immunodominant domain of the human immunodeficiency vims gp41 transmembrane protein: peptide conformation analysis using monoclonal antibodies and proton nuclear magnetic resonance spectroscopy. J. Virol. 65:1727-1734. Pancino, G., C. Chappey, W. Saurin, and P. Sonigo. 1993. B epitopes and selection pressures in feline immunodeficiency vims envelope glycoproteins. J. Virol. 67:664-672. Paxton, W., et al. 1993. Incorporation of Vpr into human immunodeficiency vims type 1 virions: requirement for the p6 region of gag and mutational analysis. J. Virol. 67: 7229- 7239. Peeters, M., A. Gueye, S. Mboup, F. Bibollet-Ruche, E. Ekaza, C. Mulanga, R. Ouedrago, R. Gandji, P. Mpele, G. Dibanga, B. Koumare, M. Saidou, E. Esu-Williams, J.-P. Lombart, W. Badombena, N. Luo, M. Vanden Haesevelde, and E. Delaporte. Geographic distribution of HIV-1 group O viruses in Africa. AIDS, in press. Peeters, M., A. Gaye, S. Mboup, W. Badombena, K. Bassabi, M. Prince-David, M. Develoux, F. Liegeois, G. van der Groen, E. Saman, and E. Delaporte. 1996. Presence of HIV-1 group O infection in West Africa. AIDS 10:343-344. Perrson M, Caothien R, Burton D (1991) Generation of diverse high affinity human monoclonal antibodies by repertoire cloning. Proc. Natl. Acad. Sci. 88:2432-2436. Robinson, W. E. Jr., M. K. Gorny, J. Y. Xu, W. M. Mitchell, and S. Zolla-Pazner. 1991. Two immunodominant domains of gp41 bind antibodies which enhance human immunodeficiency vims type 1 infection in vitro. J. Virol. 65:4169-4176. Ross,E., et al. 1991. Maturation of HIV particles assembled from the gag precursor protein requires in situ processing by gag-pol protease. Aids Res. Hum. Retrovimses 7: 475-483. Roubos E (1990) Sense-antisense complementarity of hormone receptor interaction sites. Trends Biotechnol 8: 279-281. Ruegg, C. L., C. R. Monell, and M. Strand. 1989. Inhibition of lymphoproliferation by a synthetic peptide with sequence identity to gp41 of human immunodeficiency vims type 1. J. Virol. 63:3257-3260. Saiki R, Gelfand D, Stoffel S, Scharf S, Higuchi R, Horn G, Mullis K, Erlich H (1988). Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 239 : 487-491. Saitou, N., and M. Nei. 1987. The neighbor-joining method: a new method for reconstmcting phylogenetic trees. Mol. Biol. Evol. 4:406-425. Salfeld, J., et al. 1990. A tripartite HIV-1 tat-env-rev fusion protein. EMBO J. 9: 965-970. Schulz, T. F., B. A. Jameson, L. Lopalco, A. G. Siccardi, R. A. Weiss, and J. P. Moore. 1992. Conserved stmctural features in the interaction between retroviral surface and transmembrane glycoproteins? AIDS Res. Hum. Retrovimses 8: 1571-1580. Sharp, P. M., D. L. Robertson, F. Gao, and B. Hahn. 1994. Origins and diversity of human immunodeficiency vimses. A year in review. AIDS 8:S27-S43. Simon, F. T. D. Ly, A. Baillou-Beaufils, V. Schneider-Fauveau, J. de Saint-Martin, I. Loussert-Ajaka, M.-L. Chaix, S. Saragosti, A. M. Courouce, D. Ingrand, C. Janot, and F. Brun-Vezinet. 1994. Sensitivity of screening kits for anti-HJV-1 subtype O antibodies. AIDS 8:1628-1629. Solomin, L., et al. 1990. Different sites of interaction for rev, tev and rex proteins within the rev-responsive element of the human immunodeficiency vims type 1. J. Virol. 64: 6010-6017. Soriano, V., M. Guttierez, G. Garcia-Lerma, A. Mas, R. Bravo, O. Aguilera, M. L. Perez-Labad, and J. Gonzalez-Lahoz. 1996. First case of group O infection in Spain. Vox Sang. 71:66. Starcich B, Hahn B, Shaw G et al. 1986. Identification and characterization of conserved and variable regions in the envelope gene of HTLVIII/LAV, the retrovims of AIDS. Cell 45: 637- 648. Vanden Haesevelde, M., J. L. Decourt, R. J. De Leys, B. Vanderbortght, G. van der Groen, H. Van Heuverswijn, and E. Saman. 1994. Genomic cloning and complete sequence analysis of a highly divergent human immunodeficiency vims isolate. J. Virol. 68: 1586-1596. Vanden Haesevelde, M., M. Peeters, G. Jannes, W. Janssens, G. van der Groen, P. M. Sharp, and E. Saman. 1996. Sequence analysis of a highly divergent HIV-1 -related lentivims isolated from a wild captured chimpanzee. Virology 221:346-350. Vanini, S., R. Longhi, A. Lazzarin, E. Vigo, A. G. Siccardi, and G. Viale. 1993. Discrete regions of HIV-1 gp41 defined by syncitia-inhibiting affinity-purified human antibodies. AIDS 7: 167-174. Walker G, Little M, Nadeau J, Shank D (1992). Isothermal in vitro amplification of DNA by a restriction enzyme/DNA polymerase system. Proc Natl Acad Sci USA 89:392-396. Willey R, Rutledge R, Dias S et al. (1986). Identification of conserved and divergent domains within the envelope gene of the acquired immune deficiency syndrome retrovirus. Proc Natl Acad Sci USA 83: 5038-5042. Willey R, et al. 1992. Human immunodeficiency vims type 1 Vpu protein induces rapid degradation of CD4. J. Virol. 66: 7193-7200. Wu D, Wallace B (1989). The ligation amplification reaction (LAR) - amplification of specific DNA sequences using sequential rounds of template-dependent ligation. Genomics 4:560- 569.Barany F (1991). Genetic disease detection and DNA amplification using cloned thermostable ligase. Proc Natl Acad Sci USA 88: 189-193. Zabarousky E R and Allikmets R L (1986). An improved technique for the efficient constmction of gene libraries by partial filling in of cohesive ends. Gene 42: 119-123. Zhang, L., Y. Huang, T. He, Y. Cao, and D. D. Ho. 1996. HIV-1 subtype and second-receptor use. Nature (London) 383:768. Zwart, G., H. Langedijk, L. van der Hoek, J. J. de Jong, T. F. W. Wolfs, C. Ramautarsing, M. Bakker, A. de Ronde, and J. Goudsmit. 1991. Immunodominance and antigenic variation of the principal neutralization domain of HIV- 1. Virology 181 :481 -489. Zwart, G, L. van der Hoek, M. Valk, M. T. Comelissen, E. Baan, J. Dekker, M. Koot, C. L. Kuiken, and J. Goudsmit. 1994. Antibody responses to HIV-1 envelope and gag epitopes in HIV-1 seroconverters with rapid versus slow disease progression. Virology 201:285-293. Zwart, G, T. F. W. Wolfs, R. Bookelman, S. Hartman, M. Baker, C. A. B. Boucher, C. Kuiken, and J. Goudsmit. 1993. Greater diversity of the HJV-1 V3 neutralization domain in Tanzania compared with the Netherlands: serological and genetic analysis. AIDS 7:467-474. INDICATIONS RELATING TO A DEPOSITED MICROORGANISM A. The indications made below relate to the microorganism referred to in the description on page _27 , line 7R-?q B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet kTj Name of depositary institution European Collection of Cell Cultures (ECACC) Address of depositary institution (including postal code and country) Centre for Applied Microbiology and Research (CAMR) S alisbury, Wiltshire SP4 OJG United Kingdom Date of deposit Accession Number 13 June 1997 ( 13.06.97) V97061301 C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet f~H D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States) E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e g "Accession Number of Deposit") For receiving Office use only For International Bureau use only I This sheet was received with the international application I 1 This sheet was received by the International Bureau on Authorized officer R.LR. Pet θi Authorized officer Form PCT/RO/134 (July 1992) INDICATIONS RELATING TO A DEPOSITED MICROORGANISM (PCT Rule I3bis) A. The indications made below relate to the microorganism referred to in the description on page _28 , line 8-9 B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet I v Name of depositary institution European Collection of Cell Cultures (ECACC) Address of depositary institution (including postal code and country) Centre for Applied Microbiology and Research (CAMR) S alisbury, Wiltshire SP4 OJG United Kingdom Date of deposit Accession Number 13 June 1997 ( 13.06.97) V97061302 C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet [~j D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States) E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit") For receiving Office use only For International Bureau use only V] This sheet was received with the international application I j This sheet was received by the International Bureau on: Authorized officer Authorized officer .?. *etnβr Form PCT/RO/134 (July 1992) INDICATIONS RELATING TO A DEPOSITED MICROORGANISM (PCT Rule Ubis) A. The indications made below relate to the microorganism referred to in the description on page _28 , line 1 7-] a B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet [77j Name of depositary institution European Collection of Cell Cultures (ECACC) Address of depositary institution (including postal code and country) Centre for Applied Microbiology and Research (CAMR) S alisbury, Wiltshire SP4 OJG United Kingdom Date of deposit Accession Number June 13 , 1997 ( 13. 06.97 ) V97061303 C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet [~~J D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States) E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit") For receiving Office use only For International Bureau use only fl This sheet was received with the international application j j This sheet was received by the International Bureau on: Authorized officer Authorized officer R.L.R. Pethe, Form PCT RO/I34 (July 1992) INDICATIONS RELATING TO A DEPOSITED MICROORGANISM (PCT Rule I3bis) A. The indications made below relate to the microorganism referred to in the description on page 79 , line 7^-?4 B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet Pvl Name of depositary institution European Collection of Cell Cultures (ECACC) Address of depositary institution (including postal code and country) Centre for Applied Microbiology and Research (CAMR) Salisbury , Wiltshire SP4 OJG United Kingdom Date of deposit 13 July 1998 ( 13 . 0 7.98 ) Accession Number V98071301 C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet [~~j D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States) E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit") For receiving Office use only For International Bureau use only [2 This sheet was received with the international application I j This sheet was received by the International Bureau on: Authorized officer Authorized officer Form PCT/RO/134 (July 1992) INDICATIONS RELATING TO A DEPOSITED MICROORGANISM (PCT Rule I3bιs) A. The indications made below relate to the microorganism referred to in the description B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet f TJ Name of depositary institution European Collection of Cell Cultures (ECACC) Address of depositary institution (including postal code and country) Centre for Applied Microbiology and Research (CAMR) S alisbury, Wiltshire SP4 OJG United Kingdom Date of deposit Accession Number 13 July 1998 ( 13.07.98 ] V98071302 C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet ι7 "" D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States) E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e g "Accession Number of Deposit") For receiving Office use only For International Bureau use only ^| This sheet was received with the international application j ) This sheet was received by the International Bureau on Authorized officer Authorized officer R.LR. f»ethe, Form PCT RO/134 (July 1992)

Claims: CLAIMS 1. Antigen derived from the gpl60 env precursor protein of a new HIV-1 group O strain comprising at least one amino acid sequence chosen from the following group of sequences: VQQMKI (SEQ ID NO 53), KIGPMSWYSMG (SEQ ID NO 54), MGLEKN (SEQ ID NO 55), IQQMKI (SEQ ID NO 56), KIGPLAWYSMG (SEQ ID NO 57), MGLERN (SEQ ID NO 58), QSVQEIKI (SEQ ID NO 59), KIGPMAWYSIG (SEQ ID NO 60), IGIGTT (SEQ ro NO 61), VQEIQT (SEQ ro NO 62), QTGPMAWYSIH (SEQ ID NO 63), fflLRTP (SEQ ID NO 64), IQEIKI (SEQ HD NO 65), KIGPMSWYSMG (SEQ ID NO 66), MGIGQE (SEQ ID NO 67), SVQELRI (SEQ ID NO 68), RIGPMAWYSMT (SEQ ro NO 69), MTLERD (SEQ ID NO 70), SVQEIPI (SEQ ID NO 136), and/or at least one amino acid sequence chosen from the following group of sequences: RNQQLLNLWGCKGRLIC (SEQ ID NO 71 ), CKGRLICYTSVQWNM (SEQ HD NO 72), LWGCKGRIVC (SEQ ID NO 73), SLWGCKGKLIC (SEQ ID NO 74), CKGKSIC (SEQ ID NO 75), CKGKIVC (SEQ ro NO 76), CRGRQVC (SEQ ID NO 77), CKGRLICYTSVH (SEQ ID NO 79), CKGNLIC (SEQ ID NO 80), CKGKMIC (SEQ ro NO 81 ), CKGRWC (SEQ ro NO 82), or a fragment of said antigen, said fragment consisting of at least 8, preferably 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 50 up to the maximum number of contiguous amino acids of the amino acid sequence of said antigen, with said fragment being characterized by the fact that it specifically reacts with antibodies raised against said antigen. 2. Antigen according to claim 1, characterized by an amino acid sequence comprising at least one of the following amino acid sequences: CERPGNNSIQQMKIGPLAWYSMGLERNKSSISRLAYC (SEQ ID NO 83), CERPGNNSIQQMKIGPMAWYSMGLERNKSSISRLAYC (SEQ ID NO 84), CERPGNQSVQEΠQGPMAWYSIGIGTTPANWSRIAYC (SEQ π) NO 85), CERPGNQSVQEIKIGPMAWYSIGIGTTPTYNWSRIAYC (SEQ ID NO 86), CVRPWNQTVQEIQTGPMAWYSΠΓLRTPLANLSRIAYC (SEQ ro NO 87), CQRPGNLTIQEIKIGPMSWYSMGIGQEDHSKSRNAYC (SEQ ID NO 88), CERPYYQSVQELRIGPMAWYSMTLERDRAGSDIRAAYC (SEQ ID NO 89), CERPGNHTVQQMKIGPMSWYSMGLEKNNTSSRRAFC (SEQ ID NO 90), CERTWNQS VQEIPIGPMAWYSMS VELDLNTTGSRS ADC (SEQ ID NO 135), and/or at least one amino acid sequence chosen from the following group of sequences: DQQLLNLWGCKGRIVC YTS VKWN (SEQ ID NO 91), NQQLLNLWGCKGRLVCYTSVKWNK (SEQ ID NO 92), NQQLLNLWGCKGRLVC YTS VKWNN (SEQ ID NO 138), NQQRLNLWGCKGKMICYTSVPWN (SEQ ID NO 93), NQQLLNLWGCKGKSICYTSVKWN (SEQ ID NO 94), NQQLLNLWGCKGRLICYTSVQWN (SEQ ID NO 95), NQQRLNLWGCKGKMICYTSVKWN (SEQ ID NO 96), NQQLLNLWGCKGNLICYTSVKWN (SEQ ID NO 97), NQQLLNLWGCRGRQVCYTSVIWN (SEQ ID NO 98), SQQLLNLWGCKGRLICYTSVHWN (SEQ ID NO 99), NQQLLNLWGCKGRIVC YTS VKWN (SEQ ID NO 100), NQQLLNS WGCKGKI VC YT AVKWN (SEQ ID NO 101 ), NQQLLSLWGCKGKLICYTS VKWN (SEQ ID NO 102), NQQLLNLWGCKGRLVCYTS VQWN (SEQ ID NO 137), or a fragment of said antigen, said fragment consisting of at least 8, preferably 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 50 up to the maximum number of contiguous amino acids of the amino acid sequence of said antigen, with said fragment being characterized by the fact that it specifically reacts with antibodies raised against said antigen. 3. Antigen according to any of claims 1 to 2, characterized by an amino acid sequence comprising at least one of the amino acid sequences represented by SEQ ID NO 2, SEQ ID NO 4, SEQ ID NO 6, SEQ ID NO 8, SEQ ID NO 10, SEQ ID NO 12, SEQ ID NO 14, SEQ ro NO 16, SEQ ID NO 18, SEQ ID NO 20, SEQ ro NO 22, SEQ ID NO 24, SEQ ID NO 26, SEQ HD NO 28, SEQ ID NO 30, SEQ ro NO 32, SEQ ID NO 34, SEQ ID NO 36, SEQ ID NO 38, SEQ ID NO 40 as shown in the alignment on Figure 1, and/or at least one of the amino acid sequences represented by SEQ ID NO 42, SEQ ID NO 44, SEQ ID NO 46, SEQ ro NO 48, SEQ ID NO 50, or SEQ ID NO 52 as shown in the alignment on Figure 2, and/or the amino acid sequence represented by SEQ ID NO 134, or a fragment of said antigen, said fragment consisting of at least 8, preferably 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 50 up to the maximum number of contiguous amino acids of any of the sequences represented by SEQ ID NO 2, SEQ ID NO 4, SEQ HD NO 6, SEQ ID NO 8, SEQ ro NO 10, SEQ ID NO 12, SEQ ID NO 14, SEQ ID NO 16, SEQ ID NO 18, SEQ ID NO 20, SEQ ro NO 22, SEQ ID NO 24, SEQ ID NO 26, SEQ ro NO 28, SEQ ID NO 30, SEQ ID NO 32, SEQ ID NO 34, SEQ ID NO 36, SEQ ID NO 38, SEQ ro NO 40, SEQ ID NO 42, SEQ ro NO 44, SEQ ID NO 46, SEQ ID NO 48, SEQ ID NO 50, SEQ ID NO 52, or SEQ ID NO 134 with said antigen fragment being characterized by the fact that it specifically reacts with antibodies raised against the antigen from which it is derived. 4. A polynucleic acid encoding an antigen according to any of claims 1 to 3, and more particularly a polynucleic acid comprising a nucleotide sequence chosen from the group of (I) a nucleotide sequence represented by SEQ ID NO 1, SEQ ID NO 3, SEQ ID NO 5, SEQ K) NO 7, SEQ ID NO 9, SEQ ID NO 11, SEQ ID NO 13, SEQ ID NO 15, SEQ ID NO 17, SEQ ID NO 19, SEQ ID NO 21, SEQ ID NO 23, SEQ ID NO 25, SEQ ID NO 27, SEQ ID NO 29, SEQ ID NO 31, SEQ ID NO 33, SEQ ID NO 35, SEQ ED NO 37, SEQ ID NO 39, SEQ ID NO 41, SEQ ID NO 43, SEQ ID NO 45, SEQ ID NO 47, SEQ ID NO 49, SEQ ID NO 51, SEQ ID NO 106 or (ii) a nucleotide sequence complementary to a sequence according to (I), or (iii) a nucleotide sequence showing at least 95%, preferably 96%, 97%, 98% and most preferably 99% homology to the full length of a sequence according to (I), or (iv) a nucleotide sequence according to (I) whereby T is replaced by U, or (v) a nucleotide sequence according to (I) whereby at least one nucleotide is substituted by a nucleotide analogue. 5. A nucleic acid fragment consisting of a sequence of at least 15, preferably 16, 17, 18, 19, 20, 21, 22, 23, 24, 25 up to 50 contiguous nucleotides of the sequence of a polynucleic acid according to claim 4, with said nucleic acid fragment being characterized by the fact that it selectively hybridizes to said polynucleic acid and/or selectively amplifies said polynucleic acid. 6. A virus strain belonging to HIV-1 group O, comprising in its genome a nucleic acid according to claim 4, and more particularly comprising in its genome the RNA equivalent of - one of the DNA sequences represented by SEQ ID NO 1, SEQ ID NO 3, SEQ ID NO 5, SEQ ID NO 7, SEQ ID NO 9, SEQ ID NO 11, SEQ ID NO 13, SEQ ID NO 15, SEQ ED NO 17, SEQ ro NO 19, SEQ ID NO 21, SEQ ro NO 23, SEQ ID NO 25, SEQ ID NO 27, SEQ ID NO 29, SEQ ID NO 31, SEQ ID NO 33, SEQ ED NO 35, SEQ ID NO 37, SEQ ID NO 39, SEQ ID NO 106 and/or - one of the DNA sequences represented by SEQ π) NO 41, SEQ ID NO 43, SEQ ID NO 45, SEQ HD NO 47, SEQ ro NO 49, SEQ ID NO 51, and/or - a variant sequence of the above-mentioned DNA sequences, said variant sequence showing at least 95% homology with the entire length of one of the above-mentioned sequences. 7. A virus strain according to claim 6, deposited at the ECACC on June 13, 1997 under accession number V97061301, V97061302 or V97061303, or deposited at the ECACC on July 13, 1998, under provisional accession number V98071301 or V98071302. 8. A polynucleic acid isolated from an HIV-1 group O strain according to any of claims 6 to 7. 9. An antigen isolated from an HIV-1 group O strain according to any of claims 6 to 7. 10. An antibody, preferably a monoclonal antibody, raised against an antigen or antigen fragment according to any of claims 1 to 3, or claim 9, with said antibody recognizing specifically the antigen or the antigen fragment to which it has been raised. 11. A method for detecting the presence of an HIV-1 infection, said method comprising - the detection of antibodies against HIV-1, including HIV-1 group O, using an antigen or antigen fragment according to any of claims 1 to 3, or claim 9, and/or - the detection of viral antigen originating from HIV-1, including HIV-1 group O, using an antibody according to claim 10, and/or - the detection of viral nucleic acid originating from HIV-1, including HIV-1 group O, using a nucleic acid or nucleic acid fragment according to claims 4 or 5, or claim 8, in a biological sample. 12. A kit for the detection of the presence of an HIV-1 infection, comprising at least one of the antigens or antigen fragments according to any of claims 1 to 3, or claim 9, and/or at least one of the nucleic acids or nucleic acid fragments according to claim 4 or 5, or claim 8 and/or an antibody according to claim 10. 13. A vaccine composition which provides protective immunity against an HI V- 1 infection, including an HIV-1 type O infection, comprising as an active principle at least one antigen or antigen fragment according to claims 1 to 3, or 9, or at least one nucleic acid according to claims 4 to 5, or 8 or a virus like particle (VLP) comprising at least one antigen or antigen fragment according to claims 1 to 3, or 9, or an attenuated form of at least one of the HIV-1 type O strains according to claims 6 to 7, said active principle being combined with a pharmaceutically acceptable carrier.

Inventors: DELAPORTE ERIC, PEETERS MARTINE, SAMAN ERIC, VANDEN HAESEVELDE MARLEEN, DELAPORTE, ERIC, PEETERS, MARTINE, SAMAN, ERIC, VANDEN HAESEVELDE, MARLEEN
Applicants: DELAPORTE ERIC, INNOGENETICS NV, PEETERS MARTINE, SAMAN ERIC, VANDEN HAESEVELDE MARLEEN, DELAPORTE, ERIC, INNOGENETICS N.V., PEETERS, MARTINE, SAMAN, ERIC, VANDEN HAESEVELDE, MARLEEN
Application year: 1998
Main classification: C12N15
IPC codes: A61K39, C07K14, C12N7, C12N15